Patent Publication Number: US-2023159462-A1

Title: Method for producing nitrogen-containing heteroarylcarboxamide acetic acid derivative

Description:
TECHNICAL FIELD 
     The present invention relates to a process for preparing a nitrogen-containing heteroarylcarboxamide acetic acid derivative. 
     BACKGROUND ART 
     It is reported that a [5-(3-chlorophenyl)-3-hydroxypyridine-2-carboxamide] acetic acid (hereinafter, referred to as “compound [I(A)]” or “Vadadustat”) as one kind of a nitrogen-containing heteroarylcarboxamide acetic acid derivative shows HIF-1a prolyl hydrolase inhibitory activity, and improves a blood flow, an oxygen delivery, and an energy utilization in ischemic tissue, or upregulate a production of erythropoietin for treatment of anemia (see Patent Literature 1). 
     
       
         
         
             
             
         
       
     
     According to the disclosure of the Patent Literature 1, the compound [I(A)] can be prepared according to the Reaction scheme (I) below. 
     
       
         
         
             
             
         
       
       
         
         
             
             
         
       
     
     In the Patent Literature 2, some other processes for preparing the compound [I(A)] are disclosed. According to the descriptions of this patent literature, the compound [I(A)] can be prepared according to the Reaction Scheme (2) below. 
     
       
         
         
             
             
         
       
       
         
         
             
             
         
       
     
     However, the production steps in these Reaction Schemes of starting with 2-cyano-3,5-dichloropyridine used as a starting material and ending with the compound [I(A)] are long, and the starting materials are expensive, and the production scheme is thus not said to be an optimal process for conducting on industrial scale. 
     In the Patent Literature 3, further other some processes for preparing the compound [I(A)] are disclosed. According to the descriptions of the Patent Literature, the compound [I(A)] can be prepared according to the Reaction Scheme (3) below. 
     
       
         
         
             
             
         
       
     
     However, 3,5-dichlopyridine-2-carboxylic acid used as a starting material in the Reaction Scheme is expensive, and the production scheme is thus not said to be an optimal process for conducting on industrial scale. Further, in the Patent Literature 4, which was published after the filing of JP 2019-222845 as the basis of the priority of the present application, the process for preparing the intermediate compound (3X) and the intermediate compound (4) for the compound [1(A)] as shown in Reaction Scheme (4) below are disclosed. According to the descriptions of the Patent Literature, the compound (X) and the compound (2X) can be reacted in the presence of carbon monoxide to prepare the intermediate compound (3X). Further, the intermediate compound (3X) and a 3-chlorophenyl boronic acid are reacted according to the Suzuki coupling reaction to prepare the intermediate compound (4X). 
     
       
         
         
             
             
         
       
     
     However, in the Working Examples of this application describing the preparation of the intermediate compound (4X), it is just confirmed a reaction efficiency by analyzing the reaction solution of the reaction. The patent literature neither disclose that the intermediate compound (4X) is isolated and purified and is then subjected to an instrumental analysis, nor disclose any grounds for the fact where the reaction can progress with high regioselectivity at the 5-position chlorine atom among two chlorine atoms at the 3-position and 5-position in the intermediate compound (3X) to produce the intermediate compound (4X). 
     Also as one kind of the nitrogen-containing heteroarylcarboxamide acetic acid derivative, 2-(4-hydroxy-1-methyl-7-phenoxyisoquinoline-3-carboxamide) acetic acid (hereinafter, referred to as “Compound [I(B)] or Roxadustat”) is reported. According to the Patent Literature 5, the compound [I(B)] can be prepared according to the Reaction Scheme (5) below. 
     
       
         
         
             
             
         
       
     
     However, the production steps of starting with methyl 2-chloromethyl-4-phenoxy benzoate used as a starting material and ending with the compound [I(B)] are long, and the production scheme is not said to be optimal process for conducting on industrial scale. 
     CITATION LIST 
     Patent Literature 
     Patent Literature 1: WO 2008/002576 
     Patent Literature 2: WO 2012/170377 
     Patent Literature 3: CN 105837502A 
     Patent Literature 4: WO 2020/217733 
     Patent Literature 5: WO 2014/014834 
     SUMMARY OF THE INVENTION 
     Problems to be Solved by Invention 
     The present invention provides a novel process for preparing compound [I] including the above-mentioned compound [I(A)] and compound [I(B)] each compound being useful as a medicament in an industrially advantageous manner. 
     Here the present inventors etc. tried a method for converting the compound (X) described in the above Patent Literature 3 into the compound (Y), the Suzuki coupling reaction hardly progressed, and the coupling products slightly obtained was a regioisomer which was reacted at the pyridine group at the 3-position, and accordingly, the desired product (Y) could not been prepared. Also, in the above Patent Literature 4, a reaction was conducted according to a similar method to that of the Patent Literature 3 as a reference and it can be presumed in this case that the regioisomer produced by the reaction at the pyridine group at the 3-position was produced similarly, considering the additional test results described in the Patent Literature 3 filed by the above-mentioned same inventors etc. as those of the present application. 
     Means to Solve Problems 
     The present inventors have intensively studied to solve the above problems, and a result, found out that according to the processes consisting of the below-mentioned Reaction Schemes (I) (I-I) to (I-VII), (II) (II-I) to (I-III), and (III), in contrast to the processes of the Patent Literatures 1 and 2 in which 2-cyano-3,5-dichlopyridine is used as a starting material, 2-halogeno-pyridine was subjected to an aminocarbonyl reaction to prepare the desired compound [I(A)] in more shorten steps starting with lower cost starting material, and then completed the present invention. Further, the present inventors etc. found that the desired compound (I) containing [(4-hydroxy-1-methyl-7-phenoxyisoquinoline)-3-carboxamide]acetic acid (hereinafter, referred to as “compound [I(B)]” or “Roxadustat”) can be also prepared, and then completed the present invention. 
     
       
         
         
             
             
         
       
     
     Also, though the compound (a3-1-A) below is disclosed in the Patent Literature 1, the Patent Literature 1 neither describes the solid state, the physical properties and the crystal form of the compound (a3-1-A) therein, nor suggests the presence of the crystal form of the same. 
     
       
         
         
             
             
         
       
     
     The present inventors etc. can have some findings that the residual of impurity materials becomes any problems in the preparation of the compound [I(A)]. As the results of various studies on purification method, it is possible to remove impurity materials more effectively by crystalizing the intermediate compound of the compound (a3-1-A) and then purifying the same compound to prepare the compound [I(A)] with high quality. That is, two kinds of crystal forms are existed in the compound (a3-1-A), and these two kinds of crystals can be purified to remove impurity materials effectively. Particularly, the II type crystal is better to remove impurity materials effectively. Whilst, the I type crystal is a crystal having most high thermodynamical stability, which is preferred in terms of the robustness of the process. 
     That is, the present invention includes the followings, however, which are not limited thereto.
     [1] A process for preparing a compound (a3) below which comprises reacting a compound (a1) represented by formula:   

     
       
         
         
             
             
         
       
     
     wherein 
     R 2  represents a hydrogen atom or an optionally substituted methyl group, 
     R a3  represents a phenyl group which may be optionally substituted with halogen atom, 
     R a4  represents a hydrogen atom, or alternatively, 
     R a3  and R a4  bind to each other and combine together with a pyridine group to which they are adjacent to form an isoquinoline group which may be optionally substituted with phenyloxy group, 
     Z 1  represents a chlorine atom, a bromine atom, or an iodine atom, 
     Z a2  represents a hydroxy group or a substituent represented by formula: 
     
       
         
         
             
             
         
       
     
     (wherein P 1  represents a protecting group for hydroxy group), or 
     a compound (2) represented by formula: 
     
       
         
         
             
             
         
       
     
     (wherein R 1  represents an optionally substituted alkyl group,
     a hydrogen atom, or a resin residue)   or a salt of the compound (2),   with a carbon monoxide,   in the presence of a palladium catalyst, in the presence or absence of a ligand, in the presence of a base, in a solvent, to obtain the compound (a3) represented by formula:   

     
       
         
         
             
             
         
       
     
     (wherein the symbols are the same as defined above).
     [2] The process according to [1] wherein a pressure of a carbon monoxide during the reaction is 0.01 MPa to 1 MPa.   [3] The process according to [1] or [2] wherein the molar ratio of the compound (a1) used in the reaction to the compound (2) used in the reaction is 2:1 to 1:2.   [4] The process according to any one of [1] to [3] wherein the reaction is conducted in nitriles as the solvent and at 20 to 150° C. as a reaction temperature.   [5] A compound as claimed in any one of [1] to [4] wherein the compound (a1) represents a compound (a1-5-a) represented by formula:   

     
       
         
         
             
             
         
       
     
     (wherein Z 1  represents a chlorine atom, a bromine atom or an iodine atom), and 
     the compound (a3) represents a compound (a3-3-a) represented by formula: 
     
       
         
         
             
             
         
       
     
     (wherein R 1  represents an optionally substituted alkyl group, a hydrogen atom or a resin residue).
     [6] A process which comprises conducting a reaction according to any one of [1] to [4] to prepare a compound (a3-1):   

     
       
         
         
             
             
         
       
     
     wherein R 1-1  represents an optionally substituted alkyl group or a resin residue, 
     R 2  represents a hydrogen atom or an optionally substituted methyl group, 
     R a3  represents a phenyl group which may be optionally substituted with halogen atom, and 
     R a4  represents a hydrogen atom, or alternatively, 
     R a3  and R a4  bind to each other and combine together with a pyridine group to which they are adjacent to form an isoquinoline group which may be optionally substituted with phenyloxy group, 
     Z a2  represents a hydroxy group or a substituent represented by formula: 
     
       
         
         
             
             
         
       
     
     (wherein P 1  represents a protecting group for hydroxy group), and converting the compound (a3-1) into the compound (aI) represented by formula: 
     
       
         
         
             
             
         
       
     
     wherein the symbols are the same as defined above.
     [7] The process according to any one of [1] to [4] and [6], wherein   (i) R 2  represents a hydrogen atom,   

     R a3  represents a 3-chlorophenyl group, and 
     R a4  represents a hydrogen atom, or alternatively,
     (ii) R 2  represents a methyl group, and   

     R a3  and R a4  bind to each other and combine together with a pyridine group to which they are adjacent to form a 7-phenyloxy-isoquinoline group.
     [8] The process according to [6] wherein the compound (a3-1) represents a compound (a3-2-a) represented by formula:   

     
       
         
         
             
             
         
       
     
     (wherein R 1-1  represents an optionally substituted alkyl group or a resin residue), and 
     the compound (a1) represents a compound [I(A)] represented by formula: 
     
       
         
         
             
             
         
       
         
         [9] The process according to any one of [1] to [4] and [6] wherein 
       
    
     the compound (a1) represents a compound (a1-1-a) represented by formula: 
     
       
         
         
             
             
         
       
     
     wherein Z a2  represents a hydroxy group or a substituent represented by formula: 
     
       
         
         
             
             
         
       
     
     (wherein P 1  represents a protecting group for hydroxy group), and 
     the compound (a1-1-a) is the compound (a1-1-a) prepared by reacting a compound (a4) represented by formula: 
     
       
         
         
             
             
         
       
     
     (wherein Z a3  represents a bromine atom, an iodine atom, or a trifluoromethanesulfoxy group, and Z a2  is the same as defined as above.)
     with a compound (a5) represented by formula:   

     
       
         
         
             
             
         
       
     
     (wherein X a1  and X a2  each independently represents a hydrogen atom or an alkyl group, or alternatively both of them bind to each other to form an alkylene group), 
     or an equivalent compound to the compound (a5) in the presence or absence of a base, in the presence or absence of a palladium catalyst, in the presence or absence of a ligand, in a solvent or in the absence of a solvent.
     [10] The process according to [9] wherein the compound (a1-1-a) represents a compound (a1-4-a) represented by formula:   

     
       
         
         
             
             
         
       
     
     and 
     the compound (a4) represents a compound (a4-2) represented by formula: 
     
       
         
         
             
             
         
       
     
     (wherein Z a1  represents a bromine atom or an iodine atom). 
     A process for processing a compound [I(A)] represented by formula: 
     
       
         
         
             
             
         
       
     
     which comprises
 
(i) a step of reacting a compound (a4) represented by formula:
 
     
       
         
         
             
             
         
       
     
     wherein Z a2  represents a hydroxy group or a substituent represented by formula: 
     
       
         
         
             
             
         
       
     
     (wherein P a1  represents a protecting group for hydroxy group), 
     Z a3  represents a bromine atom, an iodine atom or a trifluoromethanesulfoxy ,, and 
     a compound (a5) represented by formula: 
     
       
         
         
             
             
         
       
     
     (wherein X a1  and Xa 2  each independently represents a hydrogen atom or an alkyl group, or alternatively, both of them bind to each other to form an alkylene group) 
     or an equivalent compound to the compound (a5), in the presence or absence of a base, in the presence or absence of a palladium catalyst, in a solvent or in the absence of a solvent to prepare a compound (a1-1-a) represented by formula: 
     
       
         
         
             
             
         
       
     
     (wherein, Z a2  is the same as defined above.):
     (ii) a step of reacting the compound (a1-1-a), a compound (2-1) represented by formula:   

     
       
         
         
             
             
         
       
     
     (wherein R 1-1  represents an optionally substituted alkyl group or a resin residue) or 
     a salt of the compound (2-1), with a carbon monoxide in the presence or absence of a palladium catalyst, in the presence or absence of a ligand, in the presence or absence of a base, in a solvent or in the absence of a solvent to obtain a compound (a3-1-a) represented by formula: 
     
       
         
         
             
             
         
       
     
     (wherein R 1-1  and Z a2  are the same defined above.); and
     (iii) a step of converting the compound (a3-1-a) into the compound [I(A)] represented by formula:   

     
       
         
         
             
             
         
       
         
         The process according to [11] wherein 
       
    
     The compound (a4) represents a compound (a4-2) represented by formula: 
     
       
         
         
             
             
         
       
     
     (wherein Z a3-1  represents a bromine atom or an iodine atom), 
     the compound (a1-1-a) represents a compound represented by formula (a1-4-a): 
     
       
         
         
             
             
         
       
     
     and 
     the compound (a3-1-a) represents a compound (a3-2-a) represented by formula: 
     
       
         
         
             
             
         
       
     
     (wherein R 1-1  represents an optionally substituted alkyl group or a resin residue).
     [13] A process for preparing a compound [I(A)] represented by formula:   

     
       
         
         
             
             
         
       
     
     which comprises
     (i) a step of compound (a4-1) represented by formula:   

     
       
         
         
             
             
         
       
     
     wherein Z a2-1  represents a substituent represented by formula: 
     
       
         
         
             
             
         
       
     
     (wherein P 1  represents a protecting group for hydroxy group), and 
     Z a3  represents a bromine atom, an iodine atom, or a trifluoromethanesulfoxy ,
     with a compound (a5) represented by formula:   

     
       
         
         
             
             
         
       
     
     (wherein, X a1  and Xa 2  each independently represents a hydrogen atom, or an alkyl group, or alternatively both of them bind to each other to form an alkylene group), 
     or an equivalent compound of the compound (a5), in the presence of absence of a base, in the presence of absence of a palladium catalyst, in a solvent or in the absence of a solvent, to prepare a compound (a1-3-a) represented by formula: 
     
       
         
         
             
             
         
       
     
     (wherein Z a2-1  is the same as defined above.);
     (ii) a step of converting the compound (a1-3-a) into the compound (a1-4-a) represented by formula:   

     
       
         
         
             
             
         
       
         
         (iii) a step of reacting the compound (a1-4-a), a compound (2-1) represented by formula: 
       
    
     
       
         
         
             
             
         
       
     
     (wherein, R 1-1  represents an optionally substituted alkyl group or a resin residue),
     or salts of the compound (2-1),   with a carbon monoxide   in the presence or absence of a palladium catalyst, in the presence or absence of a ligand, in the presence or absence of a base, and in a solvent or in the absence of a solvent to prepare the compound (a3-2-a) represented by formula:   

     
       
         
         
             
             
         
       
     
     (wherein R 1-1  is the same as defined above); and
     (iv) a step of converting the compound (a3-2-a) into the compound [(1(A)] represented by formula:   

     
       
         
         
             
             
         
       
         
         [14] A process for preparing a compound (b3-1) represented by formula: 
       
    
     
       
         
         
             
             
         
       
     
     (wherein R 1  represents an optionally substituted alkyl group, a hydrogen atom, or a resin residue, 
     R 2  represents a hydrogen atom, or an optionally substituted methyl group, 
     R 3  represents a phenyl group which may be optionally substituted with halogen atom, a chlorine atom, a bromine atom, an iodine atom, or a trifluoromethanesulfoxy group, and 
     R 4  represents a hydrogen atom, or alternatively, 
     R 3  and R 4  bind to each other and combine together with a pyridine group to which they are adjacent to form an isoquinoline group which may be optionally substituted with phenyloxy group),
     (i) a step of reacting a compound (b1) represented by formula:   

     
       
         
         
             
             
         
       
     
     (wherein 
     Z 1  represents a chlorine atom, a bromine atom, or an iodine atom, 
     Z b2  represents a chlorine atom, a bromine atom or an iodine atom, and 
     R 2 , R 3 , and R 4  are the same as defined above), 
     a compound represented by formula (2): 
     
       
         
         
             
             
         
       
     
     (wherein R 1 represents an optionally substituted alkyl group,
     a hydrogen atom or a resin residue),   or a salt of the compound (2), with a carbon monoxide   in the presence of a palladium catalyst, in the presence or absence of a ligand, in the presence of a base, in a solvent to obtain a compound (b3) represented by formula:   

     
       
         
         
             
             
         
       
     
     (wherein the symbols are the same as defined above); and
     (ii) a step of reacting the compound (b3) with the compound (b4) represented by formula;   

     
       
         
         
             
             
         
       
     
     (wherein R b5  represents an optionally substituted aryl group, or an optionally substituted alkyl group)
     in the presence of a palladium catalyst, in the presence or absence of a ligand, in the presence of a base, in a solvent to prepare a compound represented by formula (b3-1):   

     
       
         
         
             
             
         
       
     
     (wherein the symbols are the same as defined above).
     [15] The process according to [14] wherein a pressure of carbon monoxide during a reaction is 0.01 MPa to 1 MPa.   [16] The process according to [14] or [15] wherein a molar ratio of the compound (b1) used in the reaction to the compound (2) used in the reaction is 2:1 to 1:2.   [17] The process according to any one of [14] to [16] wherein the reaction is conducted in nitriles as a solvent, and at 20° C. to 150° C. as a reaction temperature.   [18] A process which comprises conducting a reaction according to the process according to any one of [14] to [17] to obtain a compound (b3-2-2) represented by formula:   

     
       
         
         
             
             
         
       
     
     (wherein 
     R 1  represents an optionally substituted alkyl group, a hydrogen atom, or a resin residue, 
     R b3  represents a chlorine atom, a bromine atom, an iodine atom, or a trifluoromethanesulfoxy group), and reacting the compound (b-3-2-2) with a compound (b6) represented by formula: 
     
       
         
         
             
             
         
       
     
     (wherein 
     X b1  and X b2  each independently represents a hydrogen atom or an alkyl group, or alternatively, both of them bind to each other to form an alkylene group),
     or an equivalent compound of the compound (b6),   in the presence or absence of a base, in the presence or absence of a palladium catalyst, in a solvent or in the absence of a solvent to obtain a compound (b3-2-a) represented by formula:   

     
       
         
         
             
             
         
       
     
     (wherein the symbols are the same as defined above).
     [19] A process which comprises conducting a reaction according to the process of any one of [14] to [18] to obtain a compound (b3-1-1) represented by formula:   

     
       
         
         
             
             
         
       
     
     (wherein 
     R 1-1  represents an optionally substituted alkyl group or a resin residue, 
     R 2  represents a hydrogen atom or an optionally substituted methyl group, 
     R 3  represents a phenyl group which may be optionally substituted with halogen atom, a chlorine atom, a bromine atom, an iodine atom, or a trifluoromethanesulfoxy group, and 
     R 4  represents a hydrogen atom, or alternatively 
     R 3  and R 4  bind to each other and combine together with a pyridine group to which they are adjacent to form an isoquinoline group which may be optionally substituted with phenyloxy group), and 
     converting the compound (b3-1-1) into the compound (I) represented by formula: 
     
       
         
         
             
             
         
       
     
     (wherein the symbols are the same as defined above).
     [20] The process according to any one of [14] to [17] and [19] wherein   (i) R 2  represents a hydrogen atom,   

     R 3  represents a 3-chlorophenyl group, and 
     R 4  represents a hydrogen atom, or alternatively,
     (ii) R 2  represents a methyl group, and   

     R 3  and R 4  bind to each other and combine together with a pyridine group to which they are adjacent to form a 7-phenyloxy-isoquinoline group.
     [20] A process for preparing a compound (bI-1) represented by formula:   

     
       
         
         
             
             
         
       
     
     (wherein R 2  represents a hydrogen atom or an optionally substituted methyl group, 
     R b3-3  represents a 3-chlorophenyl group, a chlorine atom, a bromine atom, an iodine atom, or a trifluoromethanesulfoxy group, 
     Rb4-3 represents a hydrogen atom, or alternatively 
     R b3-3  and Rb 4-3  bind to each other and combine together with a pyridine group to which they are adjacent to form a 7-phenyloxy-isoquinoline group),
     which comprises   (i) a step of reacting a compound (b1-2) represented by formula:   

     
       
         
         
             
             
         
       
     
     (wherein 
     Z 1  represents a chlorine atom, a bromine atom, or an iodine atom, 
     Z b2  represents a chlorine atom, a bromine atom, or an iodine atom, and 
     R 2 , R b3-3  and R b4-3  are the same as defined above), or a compound (2-1) represented by formula: 
     
       
         
         
             
             
         
       
     
     (wherein R 1-1  represents an optionally substituted alkyl group or a resin residue), 
     or a salt of the compound (2-1),
     with a carbon monoxide   in the presence or absence of a palladium catalyst, in the presence or absence of a ligand, in the presence or absence of a base, and in a solvent or in the absence of a solvent to obtain a compound (b3-4) represented by formula:   

     
       
         
         
             
             
         
       
     
     (wherein the symbols are the same as defined above), and
     (ii) a step of reacting the compound (b3-4) and a compound represented by formula (b4):   

     
       
         
         
             
             
         
       
     
     (wherein R b5  represents an optionally substituted aryl group or an optionally substituted alkyl group)
     in the presence of a palladium catalyst, in the presence or absence of a ligand, in the presence of a base, in a solvent to obtain a compound (b3-5) represented by formula:   

     
       
         
         
             
             
         
       
     
     (wherein the symbols are the same as defined above); and
     (iii) converting the compound (b3-5) into a compound (bI-1) represented by formula:   

     
       
         
         
             
             
         
       
     
     (wherein the symbols are the same as defined above).
     [22] A compound (a1-a) represented by formula:   

     
       
         
         
             
             
         
       
     
     wherein 
     Z 1  represents a chlorine atom, a bromine atom, or an iodine atom, and 
     Z  a2  represents a hydroxy group, or a substituent represented by formula: 
     
       
         
         
             
             
         
       
     
     (wherein P 1  represents a protecting group for hydroxy group).
     [23] A crystal of the compound (a3-1-A) represented by formula:   

     
       
         
         
             
             
         
       
     
     (wherein Et represents an ethyl group).
     [24] The crystal according to [23] wherein the crystal of the compound (a3-1-A) is a I type crystal of the compound (a3-1-A).   [25] The crystal according to [23] wherein the crystal of the compound (a3-1-A) is a II type crystal of the compound (a3-1-A).   

     Effect of Invention 
     The process of the present invention can prepare a compound [I(A)] which is a nitrogen-containing heteroarylcarboxamide acetic acid and is useful as a medicine in more shorten steps, and may become an industrially advantageous process. 
    
    
     
       BRIEF DESCRIPTION OF DRAWINGS 
         FIG.  1    shows a powder X-ray diffraction pattern of the I type crystal of the compound [I(A)] of the present invention. 
         FIG.  2    shows a powder X-ray diffraction pattern of the II type crystal of the compound [I(A)] of the present invention. 
         FIG.  3    shows the  FIG.  2    which is enlarged in the vertical direction. 
     
    
    
     MODE FOR CARRYING OUT THE INVENTION 
     The definition of each group used herein is described below. 
     The term of “alkyl group” represents a straight chain or branched chain of saturated hydrocarbon chain having 1 to 6 carbon atom(s). Examples of the alkyl group include a methyl group, an ethyl group, a propyl group, an isopropyl group, a butyl group, a t-butyl group, an isobutyl group, a pentyl group, a hexyl group, and various branched chain isomers thereof, and preferably a straight chain or branched chain of saturated hydrocarbon chain having 1 to 4 carbon atoms. 
     The term of “alkylene group” represents a straight chain or branched chain of divalent saturated hydrocarbon chain having 1 to 8 carbon atom(s). Examples of the alkylene group include a methylene group, a 1,2-ethylene group, a 1,3-propylene group, a 1,1,2,2-tetramethyl-1,2-ethylene group, and various branched chain isomers thereof. 
     The term of “aryl group” represents a monocyclic or bicyclic of aromatic hydrocarbon group having 6 to 11 carbon atoms as a ring-constitute carbon atom, and includes the monocyclic aromatic hydrocarbon group such as a phenyl group; and the bicyclic aromatic hydrocarbon group having 9 to 11 carbon atoms as a ring-constitute carbon atom such as a naphthyl group, a tetrahydronaphthyl group, an indenyl group, an indanyl group and an azulenyl group. 
     The number of the substituent(s) for the terms of “Optionally substituted aryl group” and “Optionally substituted phenyl group” may be one (1) or more (such as one(1) to three(3)), and the substituents may be identical to or different from each other. Examples of the substituent include an alkyl group, a cycloalkyl group, an alkoxy group, a cyano group, a halogen atom, a hydroxy group, and a nitro group, and preferably a halogen atom (such as a chlorine atom, a bromine atom, and an iodine atom). 
     The number of the substituent(s) for the terms of “Optionally substituted alkyl group” may be one (1) or more (such as one (1) to seven (7)), and the substituents may be identical to or different from each other. Examples of the substituent include a cycloalkyl group, an alkoxy group, a halogen atom, an oxo group, and a hydroxy group. 
     The term of “cycloalkyl group” represents a cyclic saturated hydrocarbon ring having 3 to 8 carbon atoms. Examples of the cycloalkyl group include a cyclopropyl group, a cyclobutyl group, a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclooctyl group and the others. When the cycloalkyl group is referred to as herein, a fused ring and a spiro ring may be also included. 
     The term of “alkoxy group” represents a group wherein the alkyl group binds to an oxygen atom, and includes, for example, a methoxy group, an ethoxy group, a propoxy group, a butoxy group, a pentyloxy group, a hexyloxy group, and the others. 
     The term of “alkanoyl group” represents a group wherein the alkyl group binds to a carbonyl group, and includes, for example, an acetyl group, a propanoyl group, a butyryl group, a pentanoyl group, a hexanoyl group, and a heptanoyl group. 
     The term of “alkanoic acid” represents a compound wherein the alkyl group binds to a carboxy group, and includes, for example, an acetic acid, a propionic acid, a butanoic acid, a pentanoic acid, a hexanoic acid, a heptanoic acid, and the others. 
     The term of “isoquinoline group which may be optionally substituted with phenyloxy group” represents an isoquinoline group which may be optionally substituted with one (1) or more (such as one (1) to three (3)) phenyloxy group(s), and includes, for example, a 7-phenyloxy-isoquinoline group. Here the phenyloxy group may include an optionally substituted phenyloxy group, and the number of the substituent(s) may be one (1) or more (such as one (1) to three (3)), and the substituents may be identical to or different from each other. Examples of the substituent include an alkyl group, a cycloalkyl group, and an alkoxy group. 
     Examples of the term of “halogen” include a fluorine atom, a chlorine atom, a bromine atom, and an iodine atom. 
     Examples of the term of “ligand” include a phosphine ligand, as well as a nitrogen-containing heterocyclic carbene ligand, the corresponding azorium salt ligand precursors, and the others, which is not limited thereto. 
     Examples of the term of “phosphine ligand” may include a monodentate phosphine ligand, and a bidentate phosphine ligand, which is not limited thereto. 
     The term of “monodentate phosphine ligand” represents a compound wherein one (1) phosphine atom is contained in the molecule, and includes, for example, a tricyclohexylphosphine, a triphenylphosphine, a 2-di-tertbutylphosphino-3-methoxy-6-methyl-2′,4′,6′-triisopropyl-1,1′-biphenyl (RockPhos), a 2-di-tert-butylphosphino-3,4,5,6-tetramethyl-2′,4′,6′-triisopropyl-1,1′-biphenyl (Me4tBuXPhos), a 2-di-tert-butylphosphino-3,6-dimethoxy-2′,4′,6′-triisopropyl-1,1′-biphenyl (tBuBrettPhos), a 2-di-tert-butylphosphino-2′,4′,6′-triisopropyl-1,1′-biphenyl (tBuXPhos), and a 2-(di-1-adamanthylphoshino)-2′,4′,6′-triisopropyl-3,6-dimethoxybiphenyl (AdBrettPhos). 
     The term of “bidentate phosphine ligand” represents a compound wherein two (2) phosphine atoms are contained in the molecule, and includes, for example, a 1,3-bis(diphenylphosphino)propane (dppp), a 1,4-bis(diphenylphosphino)butane (dppb), a 1,5-bis(dipheylphoshino)pentane (dpppe), a 2,4-bis(diphenylphosphino)pentane (BDPP), a 1,1′-bis(diphenylphoshino)ferrocene (dppf), a 2,2′-bis(diphenylphoshino)-1,1′-binapthyl (BINAP) (rac-BINAP, (S)-BINAP, (R)-BINAP), a 2,2′-bis(di-p-tolylphoshino)-1,1′-binapthyl (tolBINAP) (rac-tolBINAP, (S)-tolBINAP, (R)-tolBINAP), and a 4,5-bis(diphenylphoshino)-9,9-dimethyl Xanthene (Xantphos). 
     The term of “nitrogen-containing heterocyclic carbene ligand” represents a ligand wherein a nitrogen-containing monocyclic five membered ring backbone having 2 to 4 nitrogen atoms as a ring-constitute atom, and the carbon atom carbene composed of the five membered ring is sandwiched between two ring-constitute nitrogen atoms, and include, for example, a 1,3-bis(2,6-diisopropylphenyl)imidazol-2-ylidene, a 1,3-bis(2,4,5-trimethylphanyl)imidazol-2-ylidene, and a 1,3-bis(2.6-bis(diphenylmethyl)-4-methylphenyl-2-imidazolilidene. 
     Examples of the term of “azorium salt ligand precursor” include an imidazolium salt ligand precursor, a triazolium salt ligand precursor, and a triazolium ligand precursor, and preferably an imidazolium salt ligand precursor. 
     The term of “resin residue” represents a resin used in a solid phase peptide synthesis, and includes, for example, a trityl resin (such as 2-chlorotrityl resin), a Merrifield resin (such as 4-chloromethyl polystyrene resin), a Wang resin (such as 4-benzyloxy benzyl alcohol resin), a hydroxy methyl polystyrene resin (such as 4-hydroxymethyl polystyrene resin), an aminomethyl polystyrene resin (such as 4-aminomethyl polystyrene resin), and a thiol resin. 
     The process for preparing a compound (I) of the present invention is specifically described below. 
     
       
         
         
             
             
         
       
     
     
       
         
         
             
             
         
       
     
     
       
         
         
             
             
         
       
     
     
       
         
         
             
             
         
       
     
     
       
         
         
             
             
         
       
     
     
       
         
         
             
             
         
       
     
     
       
         
         
             
             
         
       
     
     
       
         
         
             
             
         
       
     
     
       
         
         
             
             
         
       
     
     
       
         
         
             
             
         
       
     
     
       
         
         
             
             
         
       
     
     
       
         
         
             
             
         
       
     
     
       
         
         
             
             
         
       
     
     (in the above Reaction Schemes (I-I) to (I-VII), R 1  represents an optionally substituted alkyl group, a hydrogen atom, or a resin residue, preferably an optionally substituted alkyl group, and more preferably an alkyl group. R 1-1  represents an optionally substituted alkyl group or a resin residue, preferably an optionally substituted alkyl group, and more preferably an alkyl group. 
     R 2  represents a hydrogen atom, or an optionally substituted methyl group. 
     R a3  represents a phenyl group which may be optionally substituted with halogen atom, and R a4  represents a hydrogen atom, or alternatively, R a3  and R a4  bind to each other and combine together with a pyridine group to which they are adjacent to form an isoquinoline group which may be optionally substituted with phenyloxy group. 
     Z 1  represents a chlorine atom, a bromine atom, or an iodine atom, and preferably a chlorine atom. Z a1  represents a chlorine atom, a bromine atom, or an iodine atom, and preferably a chlorine atom or an iodine atom. 
     Z  a2  represents a hydroxy group or a substituent represented by formula: 
     
       
         
         
             
             
         
       
     
     (wherein P 1  represents a protecting group for hydroxy group), and preferably a hydroxy group. 
     Z a2-1  represent a substituent represented by formula; 
     
       
         
         
             
             
         
       
     
     (wherein P 1  represents a protecting group for hydroxy group). 
     Z a3  represents a bromine atom, an iodine atom, or a trifluoromethanesulfoxy group, and preferably a bromine atom. 
     Za 4  represents a chlorine atom, a bromine atom, an iodine atom or a trifluoromethanesulfoxy group, and preferably a bromine atom. 
     X a1  and X a2  each independently represents a hydrogen atom or an alkyl group, or alternatively, both of them bind to each other to form an alkylene group, and preferably, each represents a hydrogen atom. 
     Here examples of the substituent for the optionally substituted methyl group expressed as R 2  is not particularly limited as long as it is any substituent that can be converted into an unsubstituted methyl group. Examples of the optionally substituted methyl group include a methyl group which may be optionally substituted with dialkylamino group or alkanoyloxy group. 
     Examples of the phenyl group which may be optionally substituted with halogen atom expressed by R a3  include preferably a 3-chlorophenyl group. 
     Examples of R 2 , R a3  and R a4  include preferably (i) R 2  represents a hydrogen atom, and R a3  represents a 3-chlorophenyl group, and 
     R a4  represents a hydrogen atom, or alternatively,
     (ii) R 2  represents a methyl group, and   

     R a3  and R a4  binds to each other and combine together with a pyridine group to which they are adjacent to form a 7-phenyloxy-isoquinolinone group, 
     more preferably,
     (i) R 2  represents a hydrogen atom,   

     R a3  represents a 3-chlorophenyl group, and 
     R a4  represents a hydrogen atom. 
     A protecting group for hydroxy group expressed by Pl is not particularly limited, and preferably include a methyl group which may be optionally substituted with phenyl group which may be optionally substituted with one or two methoxy group(s) (such as a methyl, a benzyl, or a p-methoxybenzyl); an alkoxymethyl group which may be optionally substituted with trialkyl silyl group (such as a methoxy methyl, a triethylsilyl ethoxy methyl); an alkanoyl group (such as an acetyl or a pivaloyl); a sulfonyl group which may be optionally substituted with an optionally substituted methyl group or an optionally substituted phenyl group (such as a methanesulfonyl, a benzenesulfonyl, a p-toluenesulfonyl, a o-nitrobenzenesulfonyl); an optionally substituted alkyloxy carbonyl group (such as a t-butyloxycarbonyl, a benzyloxycarbonyl); a silyl group which is substituted with three groups selected from an alkyl group and an optionally substituted phenyl group (such as a triethyl silyl, a triisopropyl silyl, a tert-butyldimethyl silyl, a tert-butyldiphenyl silyl); and an aminocarbonyl group which is substituted with an optionally substituted alkyl group and an optionally substituted phenyl group (such as a dimethylaminocarbonyl, a methylphenylaminocarbonyl). More preferably, examples of the above protecting group include a methyl group which is substituted with phenyl which may be optionally substituted with one (1) or two (2) methoxy group(s) (such as a benzyl, a p-methoxybenzyl); an alkanoyl group (such as a pivaloyl); and a sulfonyl group which is substituted with optionally substituted methyl group or optionally substituted phenyl group (such as a methanesulfonyl, a benzenesulfonyl, a p-toluenesulfonyl, a o-nitrobenzesulfonyl). 
     (Step a1, Step a1-a, Step a1-1-a, Step a1-2-a, Step a1-3-a, and Step a1-4-a) 
     The compound (a1), the compound (a1-a), the compound (a1-1-a), the compound (a1-2-a), the compound (a1-4-a), or the compound (a1-5-a) (hereinafter, these compounds may be collectively referred to as “compound (a1) etc.”), the compound (2) or the compound (2-1) (hereinafter, these compounds may be collectively referred to as “compound (2) etc.”), or salts thereof, are reacted with a carbon monoxide in the presence of a palladium catalyst (here, it is referred to as “palladium catalyst (1)”) and in the presence of a base, in the presence or absence of a ligand, in a solvent to prepare the compound (a3), the compound (a3-a), the compound (a3-1-a), or the compound (a3-2-a) (hereinafter, these compounds may be collectively referred to as “compound (a3) etc.”). 
     When the compound (2) etc. wherein Rl represents a resin residue, or salts thereof are used in the present reaction, the resin residue represents a resin which is used in a solid phase peptide synthesis, and includes, for example, trityl resin (such as a 2-chlorotrityl resin), a Merrifield resin (such as a 4-chloromethyl polystyrene resin), a Wang resin (such as a 4-benzyloxy benzyl alcohol resin), a hydroxymethyl polystyrene resin (such as a 4-hydroxymethyl polystyrene resin), an aminomethyl polystyrene resin (such as a 4-aminomethyl polystyrene resin), and a thiol resin. The particle size and the loading capacity (mole number at reaction point per 1g resin: mmol/g) is not particularly limited as long as they does not affect any adverse effects on the reaction. In general, the particle size is preferably 35 to 500 μm, and the loading capacity is preferably 0.1 to 4 mmol/g. 
     Among the compound (2) etc. and salts thereof, examples of the salts of the compound (2) etc. are not particularly limited, and include, for example, a hydrochloride salt, a sulphate salt, a p-toluenesulfonate salt, a sodium salt, and a potassium salt, and preferably a hydrochloride salt. 
     Examples of the compound (2) etc., or salts thereof include preferably salts of the compound (2) etc. The equivalent amount of the compound (2) etc., or salts thereof used in the present reaction may be varied depending on the used reagent or the reaction condition, and they are usually appropriately 1 mole equivalent amount relative to the compound (a1) etc., which is, for example, 0.5 to 2.0 mole equivalent amounts, preferably 0.8 to 1.25 mole equivalents amounts, and more preferably 1 to 1.1 mole equivalent amount(s). 
     Examples of the carbon monoxide include carbon monoxide gas. The carbon monoxide gas may be used singly, or may be used in admixture with inert gas (such as nitrogen gas or argon gas). When the carbon monoxide gas is used in the present reaction, the pressure of the carbon monoxide gas during the reaction may be varied depending on the used reagent or the reaction condition, it is usually 0.01 to 1 MPa, preferably 0.02 to 0.8 MPa, and more preferably 0.05 to 0.6 MPa. Here the pressure of the carbon monoxide during the reaction as used herein represents a partial pressure in the case of a reaction system where it is used in admixture with an inert gas, and/or the case of a reaction system where the reaction solvent is made a gas state under a high temperature condition. 
     The palladium catalyst (1) can be used in the presence or absence of a ligand in the present reaction. The palladium catalyst (1) is not particularly limited as long as it is a general palladium catalyst, and include, for example, tetrakis(triphenylphosphine)palladium (0), palladium (II) acetate, bis(acetonitrile) dichloropalladium (II), dichlorobis(triphenylphosphine)palladium (II), dichloro[1,3-bis(diphenylphosphino)propane]palladium (II), [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium (II), dichloro(4,5-bis(diphenylphosphino)-9,9-dimethylxanthene)palladium (II), (4,5-bis(diphenylphosphino)-9,9-dimethylxanthene) [2-(2′-amino-1,1′-biphenyl)]palladium (II) methanesulfonate (Xantphos Pd G3), tris(dibenzylideneacetone)dipalladium (0), and palladium (II) chloride. The ligand is not particularly limited as long as it is a general ligand, and include, for example, a bidentate phosphine ligand and a monodentate phosphine ligand. 
     When the palladium catalyst (1) is used in the presence or absence of a ligand in the present reaction, preferably a palladium catalyst having one or more bidentate phosphine ligand(s), which is selected from dichloro[1,3-bis(diphenylphosphino)propane]palladium (II) and [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium (II) can be used in the absence of any ligand, or alternatively a palladium catalyst not having any ligand, which is selected from palladium (II) acetate, bis(acetonitrile)dichloropalladium (II), tris(dibenzylideneacetone)dipalladium (0), and palladium (II) chloride can be used in the presence of one or more bidentate phosphine ligand(s); and more preferably, a palladium catalyst not having any phosphine ligand, which is selected from palladium (II) acetate, bis(acetonitrile)dichloropalladium (II), tris(dibenzylideneacetone)dipalladium (0), and palladium (II) chloride can be used in the presence of one or more bidentate phosphine ligand(s); and more preferably, palladium (II) acetate can be used in the presence of one or more bidentate phosphine ligand(s). 
     Examples of the bidentate phosphine ligand include 1,3-bis(diphenylphosphino)propane (dppp), 1,4-bis(diphenylphosphino)butane (dppb), 1,5-bis(diphenylphosphino)pentane (dpppe), 2, 4-bis(diphenylphosphino)pentane (BDPP), 1, 1 ′-bis(diphenylphosphino)ferrocene (dppf), 2, 2 ′-bis(diphenylphosphino)-1,1′-binapthyl (BINAP) (rac-BINAP, (S)-BINAP, (R)-BINAP), 2,2′-bis(di-p-tolylphosphino)-1,1′-binapthyl tolBINAP) (rac-tolBINAP, (S)-tolBINAP, (R)-tolBINAP), and 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (Xantphos), and include preferably dppp, dppb, and dppf, more preferably dppp, and further preferably dppb. The equivalent amount of the palladium catalyst (1) used in the present reaction may be varied depending on the used reagent or the reaction condition, a catalytic amount of the compound (a1) etc. is usually preferred, which is for example, 0.001 to 0.1 mole equivalent amounts, and preferably 0.01 to 0.05 mole equivalent amounts, relative to the compound (a1) etc. When the reaction is carried out in the presence of a ligand, the equivalent amounts of the ligand may be varied depending on the used reagent or the reaction condition, and is usually 1 to 5 mole equivalent amount(s), and preferably 1.5 to 3 mole equivalent amounts, relative to the palladium catalyst (1). 
     The base is not particularly limited as long as it is a general base, and includes, for example, a trialkyl amine (such as triethylamine, N,N-diisopropylethylamine, tripropylamine, tributylamine), a cyclic tertiary amines (such as 4-methylmorpholine, 1,4-diazabicyclo[2.2.2]octane triethylenediamine (DABCO), 4-dimethylaminopyridine (DMAP)), a dialkylamine (such as diisopropylamine, dibutylamine, tert-butylethylamine), an alkali metal alkanoate (such as alkali metal acetate (such as sodium acetate, potassium acetate, cesium acetate, etc.), sodium propionate, sodium butanoate, sodium valerate), an optionally substituted phenylcalboxylic acid alkali metal (such as sodium salicylate, disodium terephthalate), an alkali metal carbonate (such as sodium carbonate, potassium carbonate, cesium carbonate, sodium hydrogen carbonate, potassium hydrogen carbonate), and an alkali metal phosphate (such as trisodium phosphate, tripotassium phosphate). A trialkylamine, alkali metal alkanoate, and an optionally substituted phenyl carboxylic acid alkali metal are preferably included, and trialkylamine is more preferably included. Examples of the trialkylamine include preferably triethylamine, tripropylamine, and tributylamine, and more preferably tripropylamine. The equivalent amount of a base used in the present reaction may be varied depending on the used reagent and the reaction condition, and is usually 1 to 10 mole equivalent amount(s), and preferably 2 to 5 mole equivalent amounts, relative to the compound (a1) etc. 
     The solvent is not particularly limited as long as it is a reaction-inactive solvent, and includes, for example, nitriles (such as acetonitrile, propionitrile, benzonitrile), esters (such as ethyl acetate, isopropyl acetate), aromatic hydrocarbons (such as toluene, xylene), aprotic polar solvents (such as N,N-dimethylformamide, N,N-dimethylacetamide, N-methylpyrrolidone), sulfoxides (such as dimethyl sulfoxides), ethers (such as 1,2-dimethoxyethane, 1,2-diethoxyethane, 1,3-dimethoxypropane, diglyme, cyclopentylmethyl ether, 1,4-dioxane, tetrahydrofuran, 2-methyltetrahydrofuran, diphenyl ether). Nitriles and ethers are preferably included, and nitriles is more preferably included. When nitriles are used, a production ratio of the desired compound (a3) etc. relative to the byproducts are increased. Examples of nitriles include preferably acetonitrile. Examples of ethers include preferably tetrahydrofuran. 
     The reaction temperature of the present reaction may be varied depending on the used reagent or the reaction condition, and it is usually under heating. The reaction temperature is preferably 20° C. to 150° C., more preferably 40° C. to 130° C., and further preferably 105° C. to 115° C. 
     The reaction time of the present reaction may be varied depending on the used reagent or the reaction condition, and is usually the time until the compound (a1) etc. or the compound (2) etc. has been disappeared from the reaction mixture. The reaction time is preferably 1 hour to 72 hours, more preferably 1 hour to 48 hours, and further preferably 18 hours to 48 hours. 
     (Step a2, Step a2-a, and Step a2-1-a) 
     The compound (a3-1), the compound (a3-1-a) or the compound (a3-2-a) (hereinafter, these compounds may be collectively referred to as “compound (a3-1) etc.”) is subjected to a deprotection reaction according to the process described in the Patent Literature 1 or the Patent Literature 2, to prepare the compound (a1) or the compound [I(A)] (hereinafter, these compounds may be collectively referred to as “compound (a1) etc.”). 
     As the deprotection reaction of the R 1-1 , commonly-used reactions can be applied depending on the R 1-1  of the used compound to conduct a deprotection reaction. For example, the compound (a3-1) etc. can be used in the presence of a base in a solvent to prepare the compound (a1) etc. The base is not particularly limited, and includes, for example, alkali metal hydroxides (such as sodium hydroxide, potassium hydroxide), alkali metal acetates (such as sodium acetate, potassium acetate, cesium acetate), and alkali metal carbonates (such as sodium carbonate, potassium carbonate, cesium carbonate, sodium hydrogen carbonate, potassium hydrogen carbonate). The base is preferably alkali metal hydroxides and alkali metal carbonates, and more preferably alkali metal hydroxides. Examples of the alkali metal hydroxides include preferably sodium hydroxide. Examples of the alkali metal carbonates include preferably potassium carbonate. 
     When R 1-1  represents a tert-butyl group, the compound (a3-1) etc. can be subjected to the reaction in the presence of an acid in a solvent to prepare the compound (a1) etc. The acid is not particularly limited, and includes, for example, sulfonic acids (such as methanesulfonic acid, p-toluenesulfonic acid), carboxylic acid (such as trifluoroacetic acid), and hydrogen chloride. 
     As the deprotection reaction of P 1 , commonly-used method can be applied depending on the P 1  of the used compound to conduct the deprotection reaction. Examples of the deprotection reaction include a treatment with acid (such as a treatment with hydrochloric acid), a treatment with base (such as a treatment with aqueous sodium hydroxide solution), and a hydrogenation (such as a method using a palladium catalyst under hydrogen molecule atmosphere). 
     Step a3, Step a3-1, and Step a3-2) 
     The compound (a4), the compound (a4-1), or the compound (a4-2) (hereinafter, these compounds may be collectively referred to as “compound (a4) etc.”) and the compound (a5) or an equivalent compound of the compound (a5) can be reacted in the presence of a palladium catalyst (here the palladium catalyst is referred to as “palladium catalyst (2)”) in the presence or absence of a ligand, in the presence of a base in a solvent to prepare the compound (a1-1-a) or the compound (a1-3-a) (hereinafter, these compounds may be collectively referred to as “compound (a1-1-a) etc.”). 
     The equivalent amount of the compound (a5) used in the present reaction may be varied depending on the used reagent or the reaction condition, and is usually 1 mole equivalent amount to small excess amounts, relative to the compound (a4) etc., which is for example, 1 to 1.5 mole equivalent amount(s), and preferably 1 to 1.1 mole equivalent amount(s). 
     The equivalent compound of the compound (a5) used in the present reaction includes the boroxine compound which is a compound represented by formula: 
     
       
         
         
             
             
         
       
     
     The equivalent amounts of the compound (a5-a) used in the present reaction may be varied depending on the used reagent or the reaction condition, and is usually 0.3 to 0.5 mole equivalent amounts, and preferably 0.3 to 0.4 mole equivalent amounts, relative to the Compound (a4). 
     The palladium catalyst (2) can be used in the presence or absence of a ligand in the present reaction. The palladium catalyst (2) is not particularly limited as long as it is a general palladium catalyst, and includes, for example, [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium (II), tetrakis(triphenylphosphine)palladium (0), palladium (II) acetate, bis(acetonitrile))dichloropalladium (II), dichlorobis(triphenylphosphine)palladium (II), dichloro[1,3-bis(diphenylphosphino)propane]palladium (II), tris(dibenzylideneacetone) dipalladium (0), palladium (II) chloride, a nitrogen-containing heterocyclic carbene-palladium complex catalyst (NHC-Pd complex catalyst), and Buchwald catalyst precursor. Examples of NHC-Pd complex catalyst includes allylchloro[1,3-bis(2,6-diisopropylphenyl)imidazol-2-ylidene]palladium (II) (CX21), allylchloro[1,3-bis(2,4,5-trimethylphenyl)imidazol-2-ylidene]palladium (II) (CX22), chlorophenylallyl[1,3-bis(2,6-diisopropylphenyl)imidazol-2-ylidene]palladium (II) (CX31), chlorophenylallyl[1,3-bis(2,6-diisopropylphenyl)-2-imidazolidene]palladium (II) (CX32), chlorophenylallyl 1,3-bis[2,6-bis(diphenylmethyl)-4-methylphenyl]-2-imidazolidenelpalladium (II) (CX33), and is more preferably CX33. Examples of the Buchwald catalyst precursor includes preferably a 3rd Generation Buchwald catalyst precursor (Buchwald 3rd Generation Palladacycles), and includes, for example, (2-dicyclohexylphosphino-2′,4′,6′-triisopropyl-1,1′-biphenyl)[2-(2′-amino-1,1′-biphenyl)]palladium (II) methanesulfonate (XPhos Pd G3), (2-dicyclohexylphosphino-2′, 6′-dimethoxy-1,1′-biphenyl) [2-(2′-aminol,l′-biphenyl)]palladium (II) methanesulfonate (SPhos Pd G3), (2-dicyclohexylphosphino-2′,6′-diisopropoxy-1,1′-biphenyl)[2-(2′-amino-1,1′-biphenyl)]palladium (II) methanesulfonate (RuPhos Pd G3). 
     The ligand is not particularly limited as long as it is a general ligand, and include, for example, a phosphine ligand, and a nitrogen-containing heterocyclic carbene ligand, or the corresponding azorium salt ligand precursors. Specific examples of these ligands include 1,1′-bis(diphenylphosphino)ferrocene (dppf), triphenylphosphine, 1,3-bis(diphenylphosphino)propane (dppp), tri-tert-butylphosphine, 2-di-tert-butylphosphino-3-methoxy-6-methyl-2′,4′,6′-triisopropyl-1,1′-biphenyl (RockPhos), 2-di-tert-butylphosphino-3,4,5,6-tetramethyl-2′,4′,6′-triisopropyl-1,1′-biphenyl (Me4tBuXPhos), 2-di-tert-butylphosphino-3,6-dimethoxy-2′,4′,6′-triisopropyl-1,1′-biphenyl (tBuBrettPhos), 2-di-tert-butylphosphino-2′,4′,6′-triisopropyl-1,1′-biphenyl (tBuXPhos), 2-(di-1-adamanthylphosphino)-2′,4′,6′-triisopropyl-3,6-dimethoxybiphenyl (AdBrettPhos), 2-dicyclohexylphosphino-2′,4′,6′-triisopropyl-1,1′-biphenyl (XPhos), 2-dicyclohexylphosphino-2′,6′-dimethoxy-1,1′-biphenyl (SPhos), 2-dicyclohexylphosphino-2′,6′-diisopropoxy-1,1′-biphenyl (RuPhos), 1,3-bis(2,6-diisopropylphenyl)imidazol-2-ylidene, 1,3-bis(2,4,5-trimethyl phenyl)imidazol-2-ylidene, and 1,3-bis[2,6-bis(diphenylmethyl)-4-methylphenyl]-2-imidazolidene, and the others. 
     When the palladium catalyst (2) is used in the presence of absence of a ligand in the present reaction, preferably [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium (II) can be used in the absence of a ligand, or alternatively, a palladium catalyst selected from palladium (II) acetate, bis(acetonitrile)dichloropalladium (II), tris(dibenzylideneacetone) dipalladium (0) and palladium (II) chloride can be used in the presence of 1,1′-bis(diphenylphosphino)ferrocene (dppf), and more preferably [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium (II) can be used in the absence of a ligand. 
     The equivalent amount of the palladium catalyst (2) used in the present reaction may be varied depending on the used reagent or the reaction condition, and usually a catalytic amount of the compound (a4) etc. is preferably included, which is for example, 0.001 to 0.1 mole equivalent amounts, preferably 0.002 to 0.05 mole equivalent amounts, relative to the compound (a4) etc. When the reaction is conducted in the presence of a ligand, the equivalent amount of the ligand may be varied depending on the used reagent and the reaction condition, and it is usually 1 to 5 mole equivalent amount(s) and preferably 1 to 2 mole equivalent amount(s) or 2 to 3 mole equivalent amounts, relative to the palladium catalyst (2). 
     The base is not particularly limited as long as it is a general base, and includes, for example, a trialkylamine (such as tripropylamine, N,N-diisopropylether amine, tripropylamine, N,N-diisopropylethylamine, tripropylamine, tributylamine), an alkali metal acetate (such as sodium acetate, potassium acetate, cesium acetate), an alkali metal carbonate (such as sodium carbonate, potassium carbonate, cesium carbonate, sodium hydrogen carbonate, potassium hydrogen carbonate), and an alkali metal phosphate (such as trisodium phosphate, tripotassium phosphate). An alkali metal carbonate is preferably included. The alkali metal carbonate includes preferably potassium carbonate. The equivalent amount of the base used in the present invention may be varied depending on the used reagent or the reaction condition, and is usually 1 to 10 mole equivalent amount(s), and preferably 2 to 5 mole equivalent amounts, relative to the compound (a4) etc. 
     The solvent is not particularly limited as long as it is not a reaction-inactive solvent, and includes, for example, aromatic hydrocarbons (such as toluene, xylene), esters (such as ethyl acetate, butyl acetate, isopropyl acetate), aprotic polar solvents (such as N,N-dimethyl formamide, N,N-dimethyl acetamide, N-methyl pyrrolidone), sulfoxides (such as dimethyl sulfoxides), alkyl alcohols (such as methanol, ethanol, isopropyl alcohol, t-butyl alcohol), ethers (such as 1,4-dioxane, tetrahydrofuran, 1,2-dimethoxyethane), ketones (such as methyl ketone), nitriles (such as acetonitrile, benzonitrile), and water, or mixed solvent of two or more of these solvents. The mixed solvent of water and other solvent(s) (the solvent is one or more solvent(s) selected from esters, aprotic polar solvents, sulfoxides, alkyl alcohols, ethers, ketones, and nitriles) is preferably included, and mixed solvents of water and ethers (preferably, tetrahydrofuran) or mixed solvents of water and aprotic polar solvent (preferably, N,N-dimethyl formamide) is more preferably included, and mixed solvents of water and ethers (preferably, tetrahydrofuran) is further preferably included. When the present reaction is conducted in a mixed solvent of water and the other solvent(s), the mixing ratio of each solvent (the ratio of water : the other solvent(s)) is usually a ratio of 10:1 to 1:30. When the present reaction is conducted in the mixed solvent of water and ethers, the ratio of water : ethers is preferably a ratio of 2:1 to 1:10, and more preferably a ratio of 1:1 to 1:4. When the present reaction is conducted in the mixed solvent of water and aprotic polar solvent, the ratio of water : the aprotic polar solvent is preferably a ratio of 1:1 to 1:30, and more preferably a ratio of 1:4 to 1:20. 
     The reaction temperature of the present reaction may be varied depending on the used reagent and the reaction condition, and it is usually under heating. The reaction temperature is preferably 20° C. to 120° C., more preferably 50° C. to 120° C., and further preferably 50° C. to 90° C., and further more preferably 60° C. to 90° C. (such as 70° C.) 
     The reaction time of the present reaction may be varied depending on the used reagent and the reaction condition, it is usually the time until the compound (a4) etc. has been disappeared from the reaction mixture. The reaction time is preferably 1 hour to 7 hours, and more preferable 10 hours to 20 hours. 
     (Step a4) 
     The compound (a6) and the compound (a5) can be reacted in the presence of the palladium catalyst (here the palladium catalyst is referred to as “palladium catalyst (2)”) in the presence or absence of a ligand, in the presence of a base, in a solvent to prepare the compound (a7)). 
     The present reaction can be conducted under a similar reaction condition to that of the process of the step a3. 
     (Step a5) 
     The compound (a7) can be reacted in the presence of a halogenating agent, in the presence of a base, in the presence or absence of a halogenated alkali metal, in a solvent to prepare the compound (a1-2-a). 
     Examples of the halogenating agent include a halogenating agent corresponding to Z a1  of the compound (a1-2-a) to be prepared. When the compound (a1-2-a) wherein Z a1  represents a chlorine atom (compound (a1-1-a)) is prepared, examples of the halogenating agent includes sodium hypochlorite, N-chlorosuccinimide, trichloroisocyanuric acid, and 1,3-dichloro-5,5-dimethyl hydantoin. Sodium hypochlorite, and N-chlorosuccinimide are preferably included, and sodium hypochlorite is more preferably included. When the compound (a1-2-a) wherein Z a1  represents a bromine atom, examples of the halogenating agent include N-bromosuccinimide. When the compound (a1-2-a) wherein Zal represents an iodine atom is prepared, examples of the halogenating agent include iodine molecule, and N-iodo succinimide. An iodine molecule is preferably included. When the iodine molecule is used, an iodination reaction progresses with a high regioselectivity. The equivalent amount of the halogenating agent used in the present reaction may be varied depending on the used reagent and the reaction condition, and is usually 1 mole equivalent to small excess amounts relative to the compound (a7), and is, for example, 1 to 1.5 mole equivalent amount(s), and preferably 1 to 1.2 mole equivalent amount(s). Examples of the compound (a1-2-a) prepared according to the present reaction include preferably a compound (al-2-a) wherein Z al  represents an iodine atom. 
     The base in not particularly limited, and includes, for example, an alkali metal hydroxide (such as lithium hydroxide, sodium hydroxide, potassium hydroxide), and an alkali metal carbonate (such as sodium carbonate, potassium carbonate, cesium carbonate, sodium hydrogen carbonate, potassium hydrogen carbonate). The alkali metal hydroxide is preferably included. Examples of the alkali metal hydroxides include preferably sodium hydroxide. The equivalent amount of the base used in the present reaction may be varied depending on the used reagent and the reaction condition, and is usually 1 mole equivalent amount to excess amounts relative to the compound (a7), which is, for example, 1 to 5 mole equivalent amount(s), and preferably 1.5 to 3 mole equivalent amounts. 
     As the halogenated alkali metal, the halogenated alkali metal corresponding to Zal of the compound (a1-2-a) to be prepared can be used. When the compound (a1-2-a) wherein Z a1  represents an iodine atom is prepared, examples of the halogenated alkali metal include potassium iodide, sodium iodide, and cesium iodide, and preferably potassium iodide. 
     The present reaction is preferably conducted in the presence of the halogenated alkali metal. The equivalent amount of the halogenated alkali metal used in the present reaction may be varied depending on the used reagent and the reaction condition, it is usually preferably a catalytic amount to small excess amount relative to the compound (a7), which is, for example, 0.01 to 1 mole equivalent amount(s), and preferably 0.05 to 0.3 mole equivalent amounts. 
     The solvent is not particularly limited as long as it is a reaction-inactive solvent, and includes, for example, water, ethers (such as 1,2-dimethoxyethane, diglyme, 1,4-dioxane, tetrahydrofuran, 2-methyltetrahydrofuran), or the mixed solvents of these solvents. Water is preferably included. 
     The reaction temperature of the present reaction may be varied depending on the used reagent and the reaction condition, and is preferably 0° C. to 50° C., and more preferably 10° C. to 40° C., and further preferably 20° C. to 30° C. 
     The reaction time of the present reaction may be varied depending on the used reagent and the reaction condition, and is usually the time until the compound (a7) has been disappeared from the reaction mixture. The reaction time is preferably 1 hour to 48 hours, and more preferably 5 hours to 18 hours. 
     (Step a6) 
     The Za 2-1  in the compound (a1-3-a) can be deprotected to prepare the compound (a1-4-a). 
     The present reaction can be conducted under a similar reaction condition to that of the deprotection reaction of P 1  of the step a2. 
     In the present Reaction Scheme (I) Reaction Schemes (I-I) to (I-VII), the compound (a1) etc., the compound (2) etc., the compound (a3-1) etc., the compound (a4), the compound (a5), the compound (a6), and the compound (a7) to be applied can be prepared appropriately, according to known method(s) as itself, or in combination of these methods. 
     The compound (a1) etc., the compound (2) etc., the compound (a3-1) etc., the compound (a4), the compound (5a), and the compound (a7) which are prepared in the present Reaction Scheme (I) can be converted into the compound (a1) the compound (a1) and the compound [I(A)] appropriately according to known method(s) as itself or in combination of these methods. 
     The compound wherein R 2  represents a methyl which may be optionally substituted with dialkylamino group or alkanoyloxy group can be converted into the compound wherein 
     R 2  represents a methyl group according to the method described in above-mentioned Patent Literature 5. 
     
       
         
         
             
             
         
       
     
     (In the Reaction Scheme (II-1), Z 1  and Z b2  each independently represents a chlorine atom, a bromine atom, or an iodine atom. 
     R 1  represents an optionally substituted alkyl group, a hydrogen atom, or a resin residue, and preferably an optionally substituted alkyl group, and more preferably an alkyl group. R 1-1  represents an optionally substituted alkyl group or a resin residue, preferably an optionally substituted alkyl group, and more preferably an alkyl group. 
     R 2  represents a hydrogen atom, or an optionally substituted methyl group. 
     R 3  represents a phenyl group which may be optionally substituted with halogen atom, a chlorine atom, a bromine atom, an iodine atom or a trifluoromethanesulfoxy group, R 4  represents a hydrogen atom, or alternatively R 3  and R 4  binds to each other and combine together with a pyridine group to which they are adjacent to form an isoquinoline group which may be optionally substituted with phenyloxy group. 
     R b5  represents an optionally substituted aryl group, or an optionally substituted alkyl group, preferably an optionally substituted aryl group, and more preferably an optionally substituted phenyl group, and further more preferably a phenyl group. 
     Here the optionally substituted methyl group expressed as R 2  is not particularly limited as long as it is any substituent that can be converted into an unsubstituted methyl group. Examples of the optionally substituted methyl group include a methyl group which may be optionally substituted with a dialkylamino group or an alkanoyloxy group. 
     Examples of the phenyl group which may be optionally substituted with halogen atom expressed as R 3  include preferably a 3-chlorophenyl group. 
     When R 3  represents a chlorine atom, a bromine atom, an iodine atom, or a trifluoromethanesulfoxy group, preferably all of Z′, Z b2  and R 3  represent a chlorine atom, or all of them represent a bromine atom, and more preferably all of 
     Z 1 , Z b2  and R 3  represent a chlorine atom. 
     As R 2 , R 3  and R 4 , preferably
     (i) R 2  represents a hydrogen atom,   

     R 3  represents a 3-chlorophenyl group, and 
     R 4  represents a hydrogen atom, or alternatively,
     (ii) R 2  represents a methyl group, and   

     R 3  and R 4  binds to each other and combine together with a pyridine group to which they are adjacent to form a 7-phenyloxy-isoquinoline group). 
     
       
         
         
             
             
         
       
       
         
         
             
             
         
       
     
     (In the Reaction Scheme (II-II), Z 1  and Z b2  each independently represents a chlorine atom, a bromine atom, or an iodine atom, R b3  represents a chlorine atom, a bromine atom, an iodine atom, or a trifluoromethanesulfoxy group, and preferably all of Z′, Z b2  and Z b3  represent a chlorine atom, or all of them represent a bromine atom, and more preferably all of Z 1 , Z b2  and Z b3  represent a chlorine atom. 
     R 1  represents an optionally substituted alkyl group, a hydrogen atom or a resin residue, preferably an optionally substituted alkyl group, and further preferably an alkyl group. R 1-1  represents an optionally substituted alkyl group or a resin residue, and preferably an optionally substituted alkyl group, and more preferably an alkyl group. 
     R b5  represents an optionally substituted aryl group or an optionally substituted alkyl group, preferably an optionally substituted aryl group, and more preferably an optionally substituted phenyl group, and further preferably a phenyl group. 
     X b1  and Xb 2  each independently represents a hydrogen atom or an alkyl group, or alternatively both of them binds to each other to form an alkylene group, and preferably each of them represents a hydrogen atom.) 
     
       
         
         
             
             
         
       
     
     (In Reaction Scheme (II-III), Z 1  and Z b2  each independently represents a chlorine atom, a bromine atom, or an iodine atom, preferably Z 1  and Z b2  each represents a chlorine atom, or each represents a bromine atom, more preferably, Z 1  and Z b2  each represents a chlorine atom. 
     R 1-1  represents an optionally substituted alkyl group or a resin residue, preferably represents an optionally substituted alkyl group, and more preferably represents an alkyl group. 
     R 2  represents a hydrogen atom, or an optionally substituted methyl group. 
     R b3-3  represents a 3-chlorophenyl group, a chlorine atom, a bromine atom, an iodine atom, or a trifluoromethanesulfoxy group, 
     R 4-3  represents a hydrogen atom, or alternatively, R b3-3  and R 4-3  binds to each other and combine together with a pyridine group to which they are adjacent to form a 7-phenyloxy-isoquinoline group. 
     Rb 5  represents an optionally substituted aryl group or an optionally substituted alkyl group, preferably represents an optionally substituted aryl group, and more preferably represents an optionally substituted phenyl group, and further more preferably represents a phenyl group. 
     Here the optionally substituted methyl group expressed as R 2  is not particularly limited as long as it is any substituent that can be converted into an unsubstituted methyl group. Examples of the optionally substituted methyl group include a methyl group which may be optionally substituted with dialkylamino group or alkanoyloxy group. 
     As R 2 , R b3-3 , and R b4-3   f  preferably
     (i) R 2  represents a hydrogen atom,   

     R b3-3  represents a 3-chlorophenyl group, and 
     R b4-3  represents a hydrogen atom, or alternatively,
     (ii) R 2  represents a methyl group, and   

     R b3-3  and R b4-3  binds to each other and combine together with a pyridine group to which they are adjacent to form a 7-phenyloxy-isoquinoline group) 
     (Step b1, Step b1-a, and Step b1-b) 
     The compound (b1), the compound (b1-1-1) or the compound (b1-2) (hereinafter, these compounds may be collectively referred to as “Compound (b1) etc.”), the compound (2) or salts thereof, are reacted with a carbon monoxide in the presence of a palladium catalyst (here the palladium catalyst is referred to as “palladium catalyst (b1)”) in the presence or absence of a ligand, in the presence of a base, in a solvent to prepare the compound (b3), the compound (b3-2-1) or the compound (b3-4) (hereinafter, these compounds may be collectively referred to as “Compound (b3) etc.”). 
     The present reaction can be conducted under a similar reaction condition to that of the reaction of the step al. 
     (Step b2, Step b2-a, and Step b2-b) 
     The compound (b3) etc. and the compound (b4) etc. are reacted in the presence of a palladium catalyst (here the palladium catalyst is referred to as “palladium catalyst (b2)”) in the presence or absence of a ligand, in the presence of a base, in a solvent to prepare the compound (b3-1), the compound (b3-2-2) or the compound (b3-5) (hereinafter, these compounds may be collectively referred to as “compound (b3-1) etc.”). 
     The equivalent amount of the compound (b4) used in the present reaction may be varied depending on the used reagent or the reaction condition, and is usually preferably 1 mole equivalent amount to excess amounts, which is, for example 1 to 5 mole equivalent amount(s) and preferably 1 to 1.5 equivalent amount(s). 
     The palladium catalyst (b2) can be used in the presence or absence of a ligand in the present reaction. The palladium catalyst (b2) is not particularly limited as long as it is a general palladium catalyst, and includes, for example, tetrakis(triphenylphosphine)palladium (0), dichlorobis(tricyclohexylphosphine)palladium (II), palladium (II) acetate, bis(acetonitrile)dichloropalladium (II), dichlorobis(triphenylphosphine)palladium (II), dichloro[1,3-bis(diphenylphosphino)propane]palladium (II), [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium (II), tris(dibenzylideneacetone)dipalladium (0), palladium (II) chloride, [(2-di-tert-butylphosphino-3-methoxy-6-methyl-2′,4′,6′-triisopropyl-1,1′-biphenyl)-2-(2′-aminobiphenyl)]palladium (II) methanesulfonate (RockPhos Pd G3), (2-di-tert-butylphosphino-3,4,5,6-tetramethyl-2′,4′,6′-triisopropyl-1,1′-biphenyl) (2′-amino-1,1′-biphenyl-2-yl)palladium (II) methanesulfonate (Me4tBuXPhos Pd G3), [(2-di-tert-butylphosphino-3,6-dimethoxy-2′,4′,6′-triisopropyl-1,1′-biphenyl) (2′-amino-1,1′-biphenyl-2-yl)]palladium (II) methanesulfonate (tBuBrettPhos Pd G3), [(2-di-tert-butylphosphino-2′,4′,6′-triisopropyl-1,1′-biphenyl) (2′-amino-1,1′-biphenyl-2-yl)]palladium (II) methanesulfonate (tBuXPhos Pd G3), [2-(di-1-adamanthylphosphino)-2′,4′,6′-triisopropyl-3,6-dimethoxybiphenyl][2-(2′-amino-1,1′-biphenyl)]palladium (II) methanesulfonate (AdBrettPhos Pd G3). The ligand is not particularly limited as long as it is a general ligand, and includes, for example, a monodentate phosphine ligand. 
     When the palladium catalyst (b2) is used in the presence or absence of a ligand in the present reaction, preferably, the palladium catalyst having one or more monodentate phosphine ligand selected from tetrakis(triphenylphosphine)palladium (0), dichlorobis(tricyclohexylphosphine)palladium (II), [(2-di-tert-butylphosphino-3-methoxy-6-methyl-2′,4′,6′-triisopropyl-1,1′-biphenyl)-2-(2′-aminobiphenyl)]palladium (II) methanesulfonate (RockPhos Pd G3), (2-di-tert-butylphosphino-3,4,5,6-tetramethyl-2′,4′,6′-triisopropyl-1,1′-biphenyl)(2′-amino-1,1′-biphenyl-2-yl)palladium (II) methanesulfonate (Me4tBuXPhos Pd G3), [(2-di-tert-butylphosphino-3,6-dimethoxy-2′,4′,6′-triisopropyl-1,1′-biphenyl) (2′-amino-1,1′-biphenyl-2-yl)]palladium (II) methanesulfonate (tBuBrettPhos Pd G3), [(2-di-tert-butylphosphino-2′,4′,6′-triisopropyl-1,1′-biphenyl) (2′-amino-1,1′-biphenyl-2-yl)]palladium (II) methanesulfonate (tBuXPhos Pd G3), [2-(di-1-adamanthylphosphino)-2′,4′,6′-triisopropyl-3,6-dimethoxybiphenyl][2-(2′-amino-1,1′-biphenyl)]palladium (II) methanesulfonate (AdBrettPhos Pd G3) is used in the absence of ligand, or alternatively the palladium catalyst not having a monodentate phosphine ligand selected from palladium (II) acetate, bis(bis(acetonitrile))dichloropalladium tris(dibenzylideneacetone)dipalladium (0) and palladium (II) chloride can be used in the presence of one or more monodentate phosphine ligand, more preferably the palladium catalyst not having a monodentate phosphine ligand selected from palladium (II) acetate, bis(bis(acetonitrile))dichloropalladium (II), [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium (II), tris(dibenzylideneacetone)dipalladium (0) and palladium (II) chloride can be used in the presence of one or more monodentate phosphine ligand(s), and further more preferably palladium (II) acetate can be used in the presence of one or more monodentate phosphine ligand(s). 
     Examples of the monodentate phosphine ligand include tricyclohexylphosphine, triphenylphosphine, 2-di-tert-butylphosphino-3-methoxy-6-methyl-2′,4′,6′-triisopropyl-1,1′-biphenyl (RockPhos), 2-di-tert-butylphosphino-3,4,5,6-tetramethyl-2′,4′,6′-triisopropyl-1,1′-biphenyl (Me4tBuXPhos), 2-di-tert-butylphosphino-3,6-dimethoxy-2′,4′,6′-triisopropyl-1,1′-biphenyl (tBuBrettPhos), 2-di-tert-butylphosphino-2′,4′,6′-triisopropyl-1,1′-biphenyl (tBuXPhos), 2-(di-1-adamanthylphosphino)-2′,4′,6′-triisopropyl-3, 6-dimethoxybiphenyl (AdBrettPhos), and preferably include tricyclohexylphosphine, and RockPhos. From the aspect of ligand cost, since tricyclohexylphosphine is low-cost, it is preferred. 
     The equivalent amount of the palladium catalyst (b2) used in the present reaction may be varied depending on the used reagent and the reaction condition, and is usually preferably a catalytic amount of the compound (b3) etc., which is, for example, 0.001 to 0.1 mole equivalent amounts and preferably 0.01 to 0.05 mole equivalent amounts, relative to the compound (b3) etc. When the reaction is conducted in the presence of a ligand, the equivalent amount of the ligand may be varied depending on the used reagent or the reaction condition, and is usually 1 to 5 mole equivalent amount(s), and preferably 2 to 3 equivalent amounts, relative to the palladium catalyst (b2). 
     The base is not particularly limited, and includes, for example, a trialkylamine (such as tripropylamine, N,N-diisopropylethyl amine), a sodium salt (such as sodium acetate, sodium carbonate, sodium hydrogen carbonate, trisodium phosphate), a potassium salt (such as potassium acetate, potassium carbonate, potassium hydrogen carbonate, tripotassium phosphate), a cesium salt (such as cesium acetate, cesium carbonate, cesium hydrogen carbonate). A potassium salt and a cesium salt are preferably included, and cesium salt is particularly preferably included. Examples of the potassium salt includes preferably tripotassium phosphate. Examples of the cesium salt include preferably cesium carbonate. 
     The equivalent amount of the base used in the present reaction may be varied depending on the used reagent or the reaction condition, and is usually 1 to 10 mole equivalent amount(s), and preferably 1.5 to 5 mole equivalent amounts, relative to the compound (b3) etc. 
     The solvent is not particularly limited as long as it is a reaction-inactive solvent, and include, for example, nitriles (such as acetonitrile, benzonitrile), esters (such as ethyl acetate, isopropyl acetate), aromatic hydrocarbons (such as toluene, xylene), aprotic polar solvent (such as N,N-dimethylformamide, N-methylpyrrolidone), sulfoxides (such as dimethylsulfoxide), ethers (such as 1,2-dimethoxyethane, diglyme, 1,4-dioxane, tetrahydrofuran, 2-methyltetrahydrofuran). Ethers are preferably included. Examples of the ethers include preferably 2-methyl-tetrahydrofuran. 
     The reaction temperature of the present reaction may be varied depending on the used reagent and the reaction condition, and is usually under heating. The reaction temperature is preferably 60° C. to 100° C., and more preferably 70 to 90° C. The reaction time of the present reaction may be varied depending on the used reagent or the reaction condition, and is usually the time until the compound (b3) etc. has been disappeared from the reaction mixture. The reaction time is preferably 1 hour to 72 hours, and more preferably 5 hours to 25 hours. 
     (Step b3, Step b3-a, and Step b3-b) 
     The compound (b-3-1-1), the compound (b3-3-a) or the compound (b3-5) (hereinafter, these compounds may be collectively referred to as “Compound (b3-1-1) etc.”) can be subjected to a deprotection reaction according to a similar method to those described in the Patent Literature 1 or 2 to prepare the compound (I), the compound [I(A)] or the compound (b-I-1). The present reaction can be conducted under a similar reaction condition to that of the step a2. 
     (Step b4) 
     The compound (b3-2-2) and the compound (b6) or the equivalent compound of the compound (b6) can be reacted in the presence of trialkylamine, in the presence of a palladium catalyst (here the palladium catalyst is referred to as “palladium catalyst (b3)”) in the presence or absence of a ligand in a solvent to prepare the compound (b3-2-a). 
     The equivalent amount of the compound (b6) used in the present reaction may be varied depending on the used reagent or the reaction condition, and is usually preferably 1 mole equivalent amount to small excess amounts relative to the compound (b3-2-2), which is, for example 1 to 1.5 mole equivalent amount(s), and preferably 1 to 1.1 mole equivalent amount(s). 
     The equivalent amount of the compound (b6) used in the present reaction includes, for example, the boroxine compound which is the compound (b6-a) represented by formula: 
     
       
         
         
             
             
         
       
     
     The equivalent amount of the compound (b6-a) used in the present reaction may be varied depending on the used reagent or the reaction condition, and is usually 0.3 to 0.5 mole equivalent amounts, and preferably 0.3 to 0.4 mole equivalent amounts, relative to the compound (b5-1-a). 
     The trialkylamine is not particularly limited, and includes, for example, triethylamine, and N,N-diisopropyl ethyl amine, and preferably N,N-diisopropyl ethyl amine. The equivalent amount of the trialkyl amine used in the present reaction may be varied depending on the used reagent or the reaction condition, and usually includes a range of 1 mole equivalent amount to excess amounts relative to the compound (b-3-2), which is, for example, 1 to 10 mole equivalent amount(s), and preferably 2 to 5 mole equivalent amounts. 
     The palladium catalyst (b3) can be used in the presence or absence of a ligand in the present reaction. The palladium catalyst (b3) is not particularly limited as long as it is a general palladium catalyst, and includes, for example, a nitrogen-containing heterocyclic carbene palladium complex catalyst (NHC-Pd complex catalyst (b3-1)), palladium (II) acetate, bis(acetonitrile)dichloropalladium 
     (II), tris(dibenzylideneacetone)dipalladium (0), and palladium (II) chloride. The ligand is not particularly limited as long as it is a general ligand, and includes, for example, the nitrogen-containing heterocyclic carbene ligand precursor, and the corresponding azorium salt ligand precursor (such as imidazolium salt ligand precursor). 
     When the palladium catalyst (b3) is used in the presence or absence of a ligand in the present reaction, preferably, NHC-Pd complex catalyst (b3-1) is used in the absence of a ligand, or alternatively, a palladium catalyst not having nitrogen-containing heterocyclic carbene ligand selected from palladium (II) acetate, bis(acetonitrile)dichloropalladium tris(dibenzylideneacetone)dipalladium (0), and palladium (II) chloride can be used in the presence of one or more of the nitrogen-containing heterocyclic carbene ligand(s) or the corresponding azorium salt ligand precursor(s), and more preferably the NHC-Pd complex catalyst (b3-1) can be used in the presence of a ligand. 
     Examples of the NHC-Pd complex catalyst (b3-1) include allylchloro [1,3-bis(2,6-diisopropylphenyl)imidazol-2-ylidene]palladium (II) (CX21), allylchloro [1,3-bis(2,4,5-trimethylphenyl)imidazol-2-ylidene]palladium (II) (CX22), chlorophenyl allyl [1,3-bis(2,6-diisopropylphenyl)imidazol-2-ylidene]palladium (II) (CX31), chlorophenyl allyl [1,3-bis(2, 6-diisopropylphenyl)-2-imidazolidene]palladium (II) (CX32), chlorophenyl allyl 1,3-bis[2,6-bis(diphenylmethyl)-4-methylphenyl]-2-imidazolidenelpalladium (II) (CX33). More preferably CX33 is included. Examples of the nitrogen-containing heterocyclic carbene ligand include 1,3-bis(2,6-diisopropylphenyl)imidazol-2-ylidene, 1,3-bis(2,4,5-trimethylphenyl)imidazol-2-ylidene, 1,3-bis[2,6-bis(diphenylmethyl)-4-methylphenyl]-2-imidazolidene. The corresponding azorium salt ligand precursor is not particularly limited as long as it is an azorium salt ligand precursor which is reacted with a base to produce the desired nitrogen-containing heterocyclic carbene ligand. 
     The equivalent amount of the palladium catalyst (b3) used in the present reaction may be varied depending on the used reagent or the reaction condition, and is usually, a catalytic amount of the compound (b3-2-2), which is, for example, 0.001 to 0.1 mole equivalent amounts, and preferably 0.01 to 0.05 mole equivalent amounts, relative to the compound (b3-2-2). When the reaction is conducted in the presence of a ligand, the equivalent amount of the ligand may be varied depending on the used reagent or the reaction condition, and is usually 1 to 5 mole equivalent amount(s), and preferably 2 to 3 mole equivalent amounts, relative to the palladium catalyst (b3). 
     The solvent is not particularly limited as long as it is a reaction-inactive solvent, and includes, for example, aromatic hydrocarbons (such as toluene, xylene), esters (such as ethyl acetate, butyl acetate, isopropyl acetate), aprotic polar solvents (such as N,N-dimethyl formamide, N-methylpyrrolidone), sulfoxides (such as dimethyl sulfoxides), alkyl alcohols (such as methanol, ethanol, isopropyl alcohol, t-butyl alcohol), ethers (such as 1,4-dioxane, tetrahydrofuran, 1,2-dimethoxyethane), nitriles (such as acetonitrile, benzonitrile), and water, or mixed solvents of two or more of these solvents. Preferably a mixed solvent of water and the other solvents (one or more solvent(s) selected from aromatic hydrocarbons, esters, aprotic polar solvents, sulfoxides, alkyl alcohols, ethers, and nitriles) is included, and more preferably a mixed solvent composed of water and aromatic hydrocarbons (preferably toluene), or a mixed solvent of water and alkyl alcohols (preferably methanol) is included, and further preferably, a mixed solvent composed of water and aromatic hydrocarbons (preferably toluene) is included. When the present reaction is conducted in a mixed solvent composed of water and the other solvents, the mixed ratio of each solvent is usually 10:1 to 1:10, and preferably 4:1 to 1:4. 
     The reaction temperature of the present reaction may be varied depending on the used reagent or the reaction condition, and it is usually under heating. The reaction temperature is preferably 50° C. to 120° C., and more preferably 70 C to 90° C. 
     The reaction time of the present reaction may be varied depending on the used reagent or the reaction condition, and is usually a time until the compound (b-3-2) has been disappeared from the reaction mixture. The reaction time is preferably 1 hour to 72 hours, and more preferably 10 hours to 20 hours. 
     In the present Reaction Scheme (II) Reaction Schemes (II-I) to (II-II), the compound (b1) etc., the compound (2) or salts thereof, the compound (b3) etc., the compound (b3-1-1) etc., and the compound (b3-2-2) to be applied can be prepared appropriately according to known method(s) as itself or in combination of these methods. 
     The compound (b3) etc., the compound (b3-1) etc. and the compound (b3-a) can be prepared appropriately according to known method(s) as itself or in combination of them, to convert into the compound (I), the compound [I(A)] or the compound (bI-1). 
     The compound wherein R 2  represents a methyl group which may be optionally substituted with alkylamino group or an alkanoyloxy group can prepared according to a similar method to that of the Patent Literature 5 to convert into the compound wherein R 2  represents a methyl group. 
     
       
         
         
             
             
         
       
     
     (wherein Z c1 , Zc 2 , and Zc 3  each independently represents a chlorine atom or a bromine atom, preferably Z c1 , Z c2 , and Z c3  each represents a chlorine atom or each represents a bromine atom, and more preferably Z c1 , Z c2 , and Z c3  each represents a chlorine atom. 
     R c1  represents an alkyl group. 
     R c2  represents an optionally substituted aryl group or an optionally substituted alkyl group, preferably represents an optionally substituted aryl group, and more preferably represents an optionally substituted phenyl group, and further preferably represents a phenyl group. 
     X c1  and Xc 2  each independently represents a hydrogen atom or an alkyl group, or alternatively both of them bind to each other to form an alkylene group, and preferably each represents a hydrogen atom). 
     (Step c1) 
     The compound (cl), the compound (c2), and a carbon monoxide can be reacted in the presence of a palladium catalyst (here the palladium catalyst is referred to as “palladium catalyst (c1)”), in the presence or absence of a ligand, in the presence of a base, in a solvent to prepare the compound (c3). 
     The present reaction can be conducted under a similar reaction condition to those of the methods of the step al or the step b1. 
     (Step c2) 
     The compound (c3) and the compound (c4) can be reacted in the presence of a palladium catalyst (here the palladium catalyst is referred to as “palladium catalyst (c2)”), in the presence or absence of a ligand, in the presence of a base, in a solvent, to prepare the compound (c5). 
     The present reaction can be conducted under similar reaction condition to that of the method of the step b2. 
     (Step c3) 
     The compound (c5) and the compound (c6) can be reacted in the presence of a base, in the presence of a palladium catalyst (here the palladium catalyst is referred to as “palladium catalyst (c3)”), in the presence or absence of a ligand, in the solvent to prepare the compound (c7). 
     The present reaction can be conducted under a similar reaction condition to those of the methods of the step a3 or the step b4. 
     (Step c4) 
     The compound (c3) and the compound (c6) can be reacted in the presence of a base, in the presence of a palladium catalyst (here the palladium catalyst is referred to as “palladium catalyst (c3)”), in the presence or absence of a ligand, in a solvent to prepare the compound (c8). 
     The present reaction can be conducted under a similar reaction condition to that of the reaction of the step c3. 
     (Step 5) 
     The compound (c8) and the compound (c4) can be reacted in the presence of a palladium catalyst (here the palladium catalyst is referred to as “palladium catalyst (c2)”), in the presence or absence of a ligand, in the presence of a base, in a solvent to prepare the compound (c7). 
     The present reaction can be conducted under a similar reaction condition to that of the method of the step c2. 
     (Step c6) 
     The compound (c7) can be subjected to a hydrolysis reaction according to a similar method to that described in the step b3 to prepare the compound (c9). 
     (Step c7) 
     The compound (c9) can be subjected to a deprotection reaction, for example, according to the similar method to that described in the Patent Literature 2 to prepare the compound [I(A)]. 
     In the present Reaction Scheme (III), the compound (c1), the compound (c3), the compound (c5), the compound (c7), the compound (c8), and the compound (c9) to be applied can be prepared appropriately according to known method(s) as itself or in combination of these methods. 
     The compound (c3), the compound (c5), the compound (c7), the compound (c8), and the compound (c9), which were prepared by the present Reaction Scheme (III), can be converted appropriately, according to known method(s) as itself or in combination of these methods into the compound [I(A)]. 
     The compound (a1-a) below represented by formula: 
     
       
         
         
             
             
         
       
     
     wherein Z 1  represents a chlorine atom, a bromine atom or an iodine atom, 
     Z a2  represents a hydroxy group or the substituent represented by formula: 
     
       
         
         
             
             
         
       
     
     (wherein P 1  represents a protecting group for hydroxy group) is a novel compound, which is also encompassed by the present invention. 
     Here, the protecting group for a hydroxy group expressed as Pl is not particularly limited, and include, preferably a methyl group which may be optionally substituted with one or two methoxy(s) (such as methyl, benzyl, p-methoxybenzyl), an alkoxymethyl group which may be optionally substituted with trialkylsilyl (such as methoxymethyl, triethylsilylethoxymethyl), an alkanoyl group (such as acetyl, pivaloyl), a sulfonyl group which may be optionally substituted with an optionally substituted methyl or an optionally substituted phenyl (such as methanesulfonyl, benzenesulfonyl, p-toluenesulfonyl, o-nitrobenzenesulfonyl), an optionally substituted alkyloxycarbonyl group (such as t-butyloxycarbonyl, benzyloxycarbonyl), a silyl group which is substituted with three groups selected from an alkyl group and an optionally substituted phenyl group (such as triethylsilyl, triisopropylsilyl, tert-butyldimethyl silyl, tert-butyl diphenyl silyl), and an aminocarbonyl group which is substituted with one or two substituents selected from an optionally substituted alkyl group and an optionally substituted phenyl group (such as dimethyl aminocarbonyl, methyl phenyl aminocarbonyl). More preferably, a methyl group which is substituted with a phenyl group which may be optionally substituted with one or two methoxy(s) (such as benzyl, p-methoxybenzyl), an alkanoyl group (such as pivaloyl), and a sulfonyl group which is substituted with an optionally substituted methyl group or an optionally substituted phenyl group (such as methanesulfonyl, benzenesulfonyl, p-toluenesulfonyl, o-nitrobenzenesulfonyl) is included. 
     Preferably, Z 1  represents a chlorine atom, a bromine atom, or an iodine atom, and Za 2  represents a hydroxy group. 
     More preferably, Z 1  represents a chlorine atom, and Z a2  represents a hydroxy group. 
     A crystal of the compound (a3-1-A) represented by formula: 
     
       
         
         
             
             
         
       
     
     is a novel crystal, which is also encompassed by the present invention. Two types of the crystals (that is, I type crystal and 
     II type crystal) of the compound (a3-1-A) are preferable crystals that can be removed impurity materials effectively. Among these crystals, the II type crystal is more preferred in terms of the remove of the impurity materials. Also the I type crystal is more thermodynamical stable, which is more preferred in terms of the robustness of the industrial process. 
     EXAMPLES 
     Next, the process of the present invention is explained specifically by indicating the examples as follows, but should not be limited to these examples. 
     In the present examples, each symbol has the following meaning.
     Ac: acetyl   Bn: benzyl   Boc: tert-butyloxycarbonyl   Cbz: benzyloxycarbonyl   Me: methyl   Et: ethyl   nPr: propyl   iPr/2-Pr: isopropyl   t-Bu: tert-butyl   MOM: methoxy methyl   Ms: methanesulfonyl   Piv: pivaloyl   PMB: p-methoxybenzyl   SEM: 2-(trimethylsilyl)ethoxy methyl   Ts: p-toluenesulfonyl   Pd(OAc)2: palladium (II) acetate   Pd2(dba)3: tris(dibenzylideneacetone)dipalladium (0)   Pd(dppf)Cl 2 : [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium (II)   Pd(PPh 3 ) 4 : tetrakis(triphenylphosphine)palladium (0)   P(tBu) 3 PdG2: chloro[(tri-tert-butylphosphine)-2-(2-aminobiphenyl)]palladium (II)   PdCl 2 (amphos) 2 : bis (di-tert-butyl (4-dimethylaminophenyl)phosphine)dichloro palladium (II)   CX21: allylchloro[1,3-bis(2,6-diisopropylphenyl)imidazol-2-ylidene]palladium (II)   CX22: allylchloro[1,3-bis(2,4,6-trimethylphenyl)imidazol-2-ylidene]palladium (II)   CX31: chlorophenylallyl[1,3-bis(2,6-diisopropylphenyl)imidazol-2-ylidene]palladium (II)   CX32 : chlorophenylallyl[1,3-bis(2,6-diisopropylphenyl)-2-imidazolidene]palladium (II)   CX33: 3-chlorophenylallyl1,3-bis[2,6-bis(diphenylmethyl)-4-methylphenyl]-2-imidazolidenepalladium (II)   BINAP: 2,2′-bis(diphenylphosphino)-1,1′-binapthyl   tolBINAP: 2,2′-bis(di-p-triphosphino)-1,1′-binapthyl   dppp: 1,3-bis(diphenylphosphino)propane   dppf: 1,1′-bis(diphenylphosphino)ferrocene   RockPhos: 2-di(tert-butyl)phosphino-2′,4′,6′-triisopropyl-3-methoxy-6-methyl biphenyl   PCy3: tricyclohexylphosphine   Xantphos: 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene   Et3N: triethylamine   iPr 2 NEt: N,N-diisopropyl ethyl amine   DBU: diazabicyclo undecene   DME: 1,2-dimethoxyethane   DMF: N,N-dimethylformamide   MeCN: acetonitrile   THF: tetrahydrofuran   2-MeTHF: 2-methyltetrahydrofuran   MEK: methyl ethyl ketone   aq.: aqueous solution   MsOH: methanesulfonic acid   

     The numerical value of the pressure used in the present examples represents a numerical value of absolute pressure. For example, the description of “0.6 MPa” in the examples represents “0.6 MPa abs”. 
     Example 1 
     Preparation of 2-chloro-5-(3-chlorophenyl)-3-hydroxypyridine 
     
       
         
         
             
             
         
       
     
     5-Bromo-2-chloro-3-hydroxypyridine (6.50 g, 31.184 mmol), Pd(dppf)C12 (22.9 mg, 0.031 mmol), (3-chlorophenyl)boronic acid (5.37 g, 34.302 mmol), potassium carbonate (21.55 g, 155.920 mmol), tetrahydrofuran (44.0 mL), and water (22.0 mL) were added to a reactor vessel, and the mixture was stirred under reflux for 21.5 hours. After the inner temperature was cooled to 40° C., water (44.0 mL) was added to the reaction mixture, and the resulting mixture was stirred. Further, toluene (33.0 mL) was added thereto, and the resulting mixture was stirred. After standing gently, the lower layer which was obtained by separating into two layers was recovered, and water (19.5 mL) was added thereto. 2 mol/L Hydrochloric acid (15.6 mL) was added dropwise thereto, and a crystallization by neutralization was conducted. The obtained solid was collected through filtration under reduced pressure, and dried under reduced pressure to obtain 2-chloro-5-(3-chlorophenyl)-3-hydroxypyridine group (5.10 g). (Yield 68%) 
       1 H NMR (500 MHz, DMSO-d 6 ) δ 10.93 (s, 1H), 8.21 (d, 1H, J =2.3 Hz), 7.74 (t, 1H, J=1.6 Hz), 7.62 (dt, 1H, J=7.3, 1.6 Hz), 7.48-7.55 (m, 3H) 
     Example 2 
     Preparation of 5-(3-chlorophenyl)-3-hydroxypyridine 
     
       
         
         
             
             
         
       
     
     5-Bromo-3-hydroxypyridine (8.00 g, 45.977 mmol), Pd(dppf)Cl 2  (841.0 mg, 1.149 mmol), (3-chlorophenyl)boronic acid (8.63 g, 55.172 mmol), potassium carbonate (7.28 g, 52.673 mmol), N,N-dimethyl formamide (43.60 mL), and water (5.20 mL) were added to a reactor vessel, and the mixture was stirred at 80° C. for 16 hours. Water (100 mL) and 2-methyltetrahydrofuran (50 mL) were added to the reaction mixture, and the mixture was stirred at room temperature. The resulting mixture was separated with a separatory funnel and the aqueous layer was extracted with 2-methyl tetrahydrofuran (50 mL) twice. The organic layer was combined, and the mixture was washed with saturated aqueous sodium chloride solution (150 mL). Sodium sulfate was added to the organic layer separated with a separatory funnel, and the mixture was dehydrated, and then filtered, and the resulting filtrates were concentrated under reduced pressure. Acetone (50 mL) was added to the concentrated residue, and the mixture was stirred, and then impurity materials were recovered by filtration under reduced pressure and then washed with acetone (20mL). The mixture was dried under reduced pressure to obtain 5-(3-chlorophenyl)-3-hydroxypyridine (7.59 mg) as pale brown solid. (Yield 80%)  1 H NMR (500 MHz, DMSO-d 6 ) δ 10.12 (s, 1H), 8.37 (d, 1H, J =1.8 Hz), 8.17 (d, 1H, J=2.6 Hz), 7.74 (t, 1H, J=1.8 Hz), 7.64 (dt, 1H, J=7.6, 1.5 Hz), 7.45-7.54 (m, 2H), 7.41 (t, 1H, J=2.4 Hz) 
     Example 3 
     Preparation of 5-(3-chlorophenyl)-3-hydroxy-2-iodopyridine 
     
       
         
         
             
             
         
       
     
     5-(3-Chlorophenyl)-3-hydroxypyridine (100.00 mg, 0.486 mmol), 8 mol/L aqueous sodium hydroxide solution (0.122 mL, 0.973 mmol), iodine (130.40 mg, 0.511 mmol), potassium iodide (43.10 mg, 0.258 mmol), and water (6.4 mL) were added to a reactor vessel, and the mixture was stirred at room temperature for 16 hours. Acetic acid (0.5 mL) was added to the reaction mixture, and the mixture was stirred at room temperature for 10 minutes. The precipitated solid was collected through a suction filtration, and the obtained solid was dried by heating under reduced pressure to obtain a desired 5-(3-chlorophenyl)-3-hydroxy-2-iodopyridine (140.20 mg). (Yield 86%) 
       1 H NMR (500 MHz, DMSO-d 6 ) δ 11.07 (br, 1H), 8.19 (d, 1H, J =2.1 Hz), 7.72 (t, 1H, J=1.6 Hz), 7.61 (dt, 1H, J=7.2, 1.6 Hz), 7.48-7.56 (m, 2H), 7.32 (d, 1H, J=2.3 Hz) 
     Example 4 
     reparation of ethyl 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetate 
     
       
         
         
             
             
         
       
     
     2-Chloro-5-(3-chlorophenyl)-3-hydroxypyridine (700.0 mg, 2.916 mmol), glycine ethyl ester hydrochloride salt (427.3 mg, 3.061 mmol), palladium acetate (20.5 mg, 0.087 mmol), 1,3-bis(diphenylphosphino)propane (72.7 mg, 0.175 mmol), triethylamine (1.22 mL, 8,747 mmol), and acetonitrile (35.0 mL) were added to a reactor vessel, and the atmosphere of the reaction system was purged with nitrogen and carbon monoxide successively, and pressurized with carbon monoxide at 0.6 MPa, and the resulting mixture was stirred at 110° C. for 72 hours while the pressure of the reaction system was maintained at 0.6 MPa. After the reaction mixture was concentrated under reduced pressure, acetonitrile (7.0 mL) and water (10.5 mL) were added thereto, and the mixture was stirred, and the precipitated crystals were collected through a filtration. These crystals were further dissolved into acetonitrile (3.5 mL) with heating, and ethanol (7 mL) was added thereto, and the precipitation was conducted. The resulting crystals were collected through a filtration and dried with heating under reduced pressure to obtain ethyl 2-[[5-(3-chlorophenyl)-3-hydroxypyridine carbonyl]amino]acetate (229.9 mg) (Yield 23%). 
     Further the mother liquid recovered here was concentrated under reduced pressure, and the liquid was washed with a mixed suspension of acetonitrile (0.7 mL) and ethanol (6.3 mL), and collected through a filtration and dried under reduced pressure to obtain 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]ethyl acetate (333.5 mg). (Yield 34%). 
       1 H NMR (500 MHz, DMSO-d 6 ) δ 12.30 (s, 1H), 9.51 (t, 1H, J =6.1 Hz), 8.56 (d, 1H, J=2.0 Hz), 7.92-7.95 (m, 1H), 7.77-7.83 (m, 2H), 7.52-7.58 (m, 2H), 4.15 (q, 2H, J=7.1 Hz), 4.09 (d, 2H, J=6.3 Hz), 1.22 (t, 3H, J=7.1 Hz) 
     Example 5 
     Preparation of 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]ethyl acetate 
     
       
         
         
             
             
         
       
     
     5- (3-Chlorophenyl) -3-hydroxy-2-iodopyridine (966.5 mg, 2.916 mmol), glycine ethyl ester hydrochloride salt (430.4 mg, 3.062 mmol), palladium acetate (19.7 mg, 0.087 mmol), 1, 3-bis (diphenylphosphino) propane (71.5 mg, 0.175 mmol), triethylamine (1.22 mL, 8,748 mmol), and acetonitrile (35.0 mL) were added to a reactor vessel, and the atmosphere of the reaction system was purged with nitrogen and carbon monoxide successively, and pressurized with carbon monoxide at 0.6 MPa, and the resulting mixture was stirred at 110° C. for 24 hours while the pressure of the reaction system was maintained at 0.5 MPa. After the reaction mixture was concentrated under reduced pressure, ethyl acetate (15.0 mL) and water (10 mL) were added thereto, and the mixture was extracted, and organic layer and aqueous layer were separated. The organic layer obtained here was washed with water (7.0 mL) and the aqueous layer was washed with acetate (5.00 mL), and the organic layers were combined. The organic layer was concentrated under reduced pressure, and the concentrated residue was purified by column chromatography to obtain ethyl 2-[[5-(3-chlorophenyl)-3-hydroxypyridine carbonyl]amino]acetate (herein, referred to as “Compound (a3-1-A)”) (600.3 mg). (Yield 61%) 
       1 H NMR (500 MHz, DMSO-d 6 ) δ 12.30 (s, 1H), 9.50 (t, 1H, J =6.1 Hz), 8.55 (d, 1H, J=2.0 Hz), 7.92-7.95 (m, 1H), 7.77-7.83 (m, 2H), 7.52-7.58 (m, 2H), 4.15 (q, 2H, J=7.1 Hz), 4.09 (d, 2H, J=6.3 Hz), 1.22 (t, 3H, J=7.1 Hz) 
     Example 6 
     Preparation of 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic acid 
     
       
         
         
             
             
         
       
     
     Ethyl 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetate (200.0 mg, 0.597 mmol), 1 mol/L aqueous sodium hydroxide solution (1.0mL, 1.000 mmol), and tetrahydrofuran (1.0 mL) were added to a reactor vessel, and the mixture was stirred at 55° C. for 4.5 hours. 8 mol/L Aqueous sodium hydroxide solution (0.25 mL, 2.000 mmol) was supplemented, and the reaction was completed. 2 mol/L Hydrochloric acid (1.5 mL, 2.987 mmol) was added to the reaction mixture, and the solvent was concentrated under reduced pressure. 2 mol/L Aqueous sodium hydroxide solution and ethyl acetate were added to the residue, and a back-extraction was conducted, and 2 mol/L hydrochloric acid and ethyl acetate were added to the separated aqueous layer, and the extraction procedure was conducted. Sodium sulfate was added to the resulting organic layer, and the mixture was dehydrated and filtered, and the filtrates were concentrated under reduced pressure. The concentrated residue was dried with heating under reduced pressure to 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic acid (151.3 mg). (Yield 82%) 
       1 H NMR (500 MHz, DMSO-d 6 ) δ 12.81 (br, 1H), 12.38 (s,  1 H), 9.37 (t, 1H, J=12.2 Hz), 8.55 (s, 1H), 7.93 (s, 1H), 7.75-7.84 (m, 2H), 7.50-7.59 (m, 2H), 4.02 (d, 2H, J=12.2 Hz) 
     Example 7 
     Preparation of 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic acid 
     
       
         
         
             
             
         
       
     
     Tert-butyl 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetate (102.1 mg, 0.281 mmol), water (1.0 mL), and methanesulfonic acid (1.0 mL, 15 mmol) were added to reactor vessel, and the atmosphere of the reaction system was purged with nitrogen, and the mixture was then stirred at 50° C. for 15 hours. The progression of reaction was evaluated by HPLC to found that starting materials/desired products =0.4/95.0 (area percentage). 
     Example 8 
     Preparation of 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic acid 
     
       
         
         
             
             
         
       
     
     Tert-butyl 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetate (101.3 mg, 0.279 mmol), tetrahydrofuran (1.0 mL), and 1 mol/L sodium hydroxide (1.0 mL) were added to a reactor vessel, and the atmosphere of the reaction system was purged with nitrogen, and the mixture was then stirred at 50° C. four 15 hours. After the reaction mixture was cooled to a room temperature, 2 mol/L hydrochloric acid was added thereto, and the mixture was adjusted to pH 2, and the solvent was removed by concentration under reduced pressure. 
     The resulting residue was washed with water and hexane, and then dried with heating (50° C.) under reduced pressure to obtain 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino] acetic acid (73.2 mg). (Yield 85%) 
       1 H NMR (500 MHz, DMSO-d 6 ) δ 12.82 (br, 1H), 12.38 (s,  1 H), 9.37 (t, 1H, J=12.2 Hz), 8.55 (s, 1H), 7.93 (s, 1H), 7.75-7.84 (m, 2H), 7.50-7.59 (m, 2H), 4.02 (d, 2H, J=12.2 Hz) 
     Example 9 
     Preparation of methyl 2-[(3,5-dichlopyridine-2-carbonyl)amino]acetate 
     
       
         
         
             
             
         
       
     
     2,3,5-Trichloropyridine (2.09 g, 11.5 mmol), glycine methyl ester hydrochloride salt (1.73 g, 13.8 mmol), dppp (284.6 mg, 0.690 mmol), Pd(OAc) 2  (77.7 mg, 0.346 mmol), triethylamine (3.49 g, 34.5 mmol), and acetonitrile (21 mL) were added to a reactor vessel, and the atmosphere of the reaction system was purged with nitrogen and carbon monoxide successively, and pressurized with carbon monoxide at 0.6 MPa, and the resulting mixture was stirred at 110° C. for 12 hours while the pressure of the reaction system was maintained at 0.6 MPa. The reaction mixture was filtered under reduced pressure, and washed with acetonitrile (10 mL). A cake was suspended into acetonitrile (20 mL), and filtered again, and washed with acetonitrile (20 mL). These filtrates and the wash solutions were combined, and the mixtures were concentrated under reduced pressure. Acetonitrile (3 mL) was added to the concentrated residue, and the mixture was heated to 75° C. to dissolve the participated materials, and the mixture was stirred at room temperature, and then washed with water (11.5 mL), and further stirred at room temperature. 
     The participated materials were filtered under reduced pressure, and washed with mixed solution of acetonitrile : water=1:1 (3.0 mL) twice. The mixture was dried under reduced pressure to obtain methyl 2-[(3,5-dichloro pyridine-2-carbonyl)amino]acetate (1.90 g) as white powder. (Yield 63%) 
       1 1-1 NMR (500 MHz, CDCl 3 ) δ 8.45 (d, 1H, J=2.0 Hz), 8.18 (s, 1H), 7.86 (d, 1H, J=2.1 Hz), 4.24 (d, 2H, J=5.5 Hz), 3.80 (s, 3H) 
     Example 10 
     Preparation of tert-butyl 2-[(3,5-dichloropyridine-2-carbonyl)amino]acetate 
     
       
         
         
             
             
         
       
     
     2,3,5-Trichloropyridine (2.62 g, 14.4 mmol), glycine tert-butyl ester hydrochloride salt (2.52 g, 15.1 mmol), dppp (355.3 mg, 0.861 mmol), Pd(OAc)2 (96.9 mg, 0.432 mmol), triethylamine (4.36 g, 43.1 mmol), and acetonitrile (26 mL) were added to were added to a reactor vessel, and the atmosphere of the reaction system was purged with nitrogen and carbon monoxide successively, and pressurized with carbon monoxide at 0.6 MPa, and the resulting mixture was stirred at 110° C. for 12 hours. After the reaction mixture was concentrated under reduced pressure, a cake was washed with acetonitrile (26 mL). The filtrates and the wash solutions were combined, and the mixture was concentrated under reduced pressure to 10.4 g. Water (13 mL) was added thereto, and the mixture was stirred at room temperature. The precipitated materials were filtered under reduced pressure, and washed with mixed solution (6.5 mL) of acetonitrile water =1:1 twice. The mixture was concentrated under reduced pressure to obtain tert-butyl 2-[(3,5-dichloropyridine-2-carbonyl)amino]acetate (3.22 g). (Yield 74%) 
       1 H NMR (500 MHz, CDCl 3 ) δ 8.44 (d, 1H, J=2.1 Hz), 8.15 (s, 1H), 7.86 (d, 1H, J=2.1 Hz), 4.12 (d, 2H, J=5.3 Hz), 1.50 (s, 9H) 
     Example 11 
     Preparation of methyl 2-[(5-chloro-3-hydroxypyridine-2-carbonyl)amino]acetate 
     
       
         
         
             
             
         
       
     
     Methyl 2-[(3,5-dichloropyridine-2-carbonyl)amino]acetate (3.00 g, 11.4 mmol), Pd2(dba)3 (313.2 mg, 0.3420 mmol), RockPhos (320.8 mg, 0.6844 mmol), cesium carbonate (8.18 g, 25.1 mmol), (E)-benzaldehyde oxime (1.80 g, 14.9 mmol), and 2-MeTHF (35 mL) were added to a reactor vessel, and the atmosphere of the reaction system was purged with nitrogen, and the mixture was then stirred at 85° C. for 20 hours. The reaction mixture was concentrated under reduced pressure, and water (75 mL) and chloroform (70 mL) were added to the concentrated residue, and the mixture was stirred at room temperature. The mixture was separated with a separatory funnel, and the aqueous layer was extracted with chloroform (70 mL) twice. The organic layers were combined, and sodium sulfate was added thereto, and the mixture was dehydrated, and filtered, and the filtrates were concentrated under reduced pressure. Methanol (25 mL) was added to the concentrated residue, and the mixture was stirred, and the precipitated materials were then filtered under reduced pressure, and washed with methanol (15 mL). The mixture was dried under reduced pressure to obtain methyl 2-[(5-chloro-3-hydroxypyridine-2-carbonyl)amino]acetate (807.8 mg) as a pale green solid. (Yield 29%) 
       1 H NMR (500 MHz, DMSO-d 6 ) δ 12.44 (br, 1H), 9.53 (brt, 1H, 
     J=5.7 Hz), 8.25 (d, 1H, J=2.0 Hz), 7.70 (d, 1H, J=2.1 Hz), 4.08 (d, 2H, J=6.1 Hz), 3.67 (s, 3H) 
     Example 12 
     Preparation of tert-butyl 2-[(5-chloro-3-hydroxypyridine-2-carbonyl)amino]acetate 
     
       
         
         
             
             
         
       
     
     Tert-butyl 2-[(3,5-dichloropyridine-2-carbonyl)amino]acetate (2.99 g, 9.83 mmol), Pd2(dba)3 (270.4 mg, 0.295 mmol), RockPhos (276.1 mg, 0.590 mmol), cesium carbonate (7.1 g, 21.6 mmol), (E)-benzaldehyde oxime (1.55 g, 12.8 mmol), and 2-MeTHF (20 mL) were added to a reactor vessel, and the atmosphere of the reaction system was purged with nitrogen, and the mixture was then stirred at 80° C. for 21 hours. The reaction mixture was cooled to room temperature, and the solid component was filtered. The solid component was dissolved by adding 2 mol/L hydrochloric acid (12 mL) and 2-MeTHF (20 mL), and the aqueous layer was separated, and the organic layer was then concentrated under reduced pressure. The solid concentrated residue was washed with n-heptane, and the mixture was dried under reduced pressure, and was further purified by a column chromatography to obtain tert-butyl 2-[(5-chloro-3-hydroxypyridine-2-carbonyl)amino]acetate (1.40 g) as a white solid (1.40 g). (Yield 50%) 
       1 H NMR (500 MHz, CDCl 3 ) δ 12.02 (s, 1H), 8.34-8.20 (brs, 1H), 8.03 (d, 1H, J=2.0 Hz), 7.33 (d, 1H, J=2.0 Hz), 4.12 (d, 2H, J=5.5 Hz), 1.51 (s, 9H) 
     Example 13 
     Preparation of tert-butyl 2-[(5-chloro-3-hydroxypyridine-2-carbonyl)amino]acetate 
     
       
         
         
             
             
         
       
     
     Tert-butyl 2-[(3,5-dichloropyridine-2-carbonyl)amino]acetate (6.00 g, 19.7 mmol), Pd(OAc)2 (132.6 mg, 0.590 mmol), PCy3 (331.1 mg, 1.180 mmol), cesium carbonate (14.1 g, 43.3 mmol), (E)-benzaldehyde oxime (3.10 g, 25.6 mmol), and 2-MeTHF (40 mL) were added to a reactor vessel, and the atmosphere of the reaction system was purged with nitrogen, and the mixture was then stirred at 80° C. for 21 hours. The reaction mixture was cooled to room temperature, and was filtered under reduced pressure, and the solid component was collected through filtration. 2 mol/L Hydrochloric acid (21.6 mL, 43.3 mmol) and ethyl acetate (40 mL) were added to the solid component, and the aqueous layer was separated, and the organic layer was then concentrated under reduced pressure. The concentrated residue was purified by column chromatography to obtain tert-butyl 2-[(5-chloro-3-hydroxypyridine-2-carbonyl)amino]acetate (4.45 g) as a white solid. (Yield 79%) 
       1 H NMR (500 MHz, DMSO-d 6 ) δ 12.51 (s, 1H), 9.41 (brt, 1H, J=6.0 Hz), 8.24 (d, 1H, J=2.1 Hz), 7.70 (d, 1H, J=2.1 Hz), 3.95 (d, 2H, J=6.3 Hz), 1.42 (s, 9H) 
     Example 14 
     Preparation of tert-butyl 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetate 
     
       
         
         
             
             
         
       
     
     Tert-butyl 2-[(5-chloro-3-hydroxypyridine-2-carbonyl)amino]acetate (1.00 g, 3.50 mmol), CX21 (100.6 mg, 0.176 mmol), (3-chlorophenyl)boronic acid (572.4 mg, 3.66 mmol), toluene (5.0 mL), water (15 mL), and N,N-diisopropyl ethyl amine (1.26 g, 9.77 mmol) were added to a reactor vessel, and the atmosphere of the reaction system was purged with nitrogen, and the mixture was then stirred at 85° C. for 15 hours. After cooled to room temperature, the mixture was separated with a separatory funnel, and the aqueous layer was extracted with toluene (10 mL). The organic layers were combined, and sodium sulfate was added thereto, and the mixture was dehydrated and filtered, and then concentrated under reduced pressure. The concentrated residue was purified by a column chromatography. The concentrated residue was dissolved by adding ethyl acetate (500 pL), and washed with n-heptane (20 mL), and the precipitated materials were then collected through filtration. The mixture was dried under reduced pressure to obtain tert-butyl 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetate (462.3 mg). (Yield 36%) 
       1 H NMR (500 MHz, DMSO-d 6 ) δ 12.34 (s, 1H), 9.40, (t, 1H, J =6.2 Hz), 8.55 (d, 1H, J=1.9 Hz), 7.93 (s, 1H), 7.84-7.80 (m, 1H), 7.79 (d, 1H, J=2.0 Hz), 7.57-7.53 (m, 2H), 3.98 (d, 2H, J=6.2 Hz), 1.44 (s, 9H) 
     Example 15 
     Preparation of 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic acid 
     
       
         
         
             
             
         
       
     
     Tert-butyl 2-[[5-(3-chlorophenyl)-3-hydroxypyridine carbonyl]amino]acetate (101.3 mg, 0.2792 mmol), 1 mol/L aqueous sodium hydroxide solution (1.0 mL, 1.0 mmol), and THF (1.0 mL) were added to a reactor vessel, and the mixture was stirred at 50° C. for 15 hours to progress the reaction. After cooled to room temperature, the mixture was adjusted with 2 mol/L hydrochloric acid (300 pL) to pH 2.0. This mixture was concentrated under reduced pressure at 35° C. as an outer bath temperature, and THF was removed. After the concentrated residue was stirred at room temperature for 30 minutes, the precipitated solid was filtered. The solids that were collected by filtration were washed with water (2.0 mL) and n-hexane (2.0 mL), and the mixture was dried under reduced pressure to obtain 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic acid (73.2 mg). (Yield 86%) 
       1 H NMR (500 MHz, DMSO-d 6 ) δ 12.82 (brs, 1H), 12.38 (s,  1 H), 9.37, (t, 1H, J=6.2 Hz), 8.55 (d, 1H, J=1.9 Hz), 7.95-7.92 (m, 1H), 7.83-7.80 (m, 1H), 7.79 (d, 1H, J=1.8 Hz), 7.56-7.53 (m, 2H), 4.02 (d, 2H, J=6.2 Hz) 
     Example 16 
     Preparation of methyl 2-[(3,5-dichloropyridine-2-carbonyl)amino]acetate 
     
       
         
         
             
             
         
       
     
     2,3,5-Trichloropyridine (700 mg, 3.84 mmol), glycine methyl ester hydrochloride salt (1.2 equivalents), a ligand (6.0 mol %), Pd(OAc)2 (3.0 mol %), triethylamine (3.0 equivalents), and solvent (35 mL) were added to a reactor vessel, and the atmosphere of the reaction system was purged with nitrogen and carbon monoxide successively, and pressurized with carbon monoxide at 0.6 MPa, and the mixture was stirred at 110° C. for 5 hours while the pressure of the reaction system was maintained at 0.6 MPa. The progression of reaction was evaluated by HPLC and the results are shown in Table 1 below. 
     
       
         
           
               
               
             
               
                   
                 TABLE 1 
               
             
            
               
                   
                   
               
               
                   
                 HPLC measurement 
               
               
                   
                 results [area %] 
               
            
           
           
               
               
               
               
               
               
            
               
                   
                   
                   
                 Desired 
                 Starting 
                   
               
               
                 Run 
                 Solvent 
                 Ligand 
                 products 
                 materials 
                 Others 
               
               
                   
               
            
           
           
               
               
               
               
               
               
            
               
                 1 
                 toluene 
                 Xantphos 
                 10.5 
                 86.2 
                 3.3 
               
               
                 2 
                 DME 
                 Xantphos 
                 12.0 
                 83.7 
                 4.4 
               
               
                 3 
                 diglyme 
                 Xantphos 
                 15.0 
                 79.2 
                 5.8 
               
               
                 4 
                 anisole 
                 Xantphos 
                 16.1 
                 73.6 
                 10.3 
               
               
                 5 
                 DMF 
                 Xantphos 
                 24.1 
                 57.3 
                 18.6 
               
               
                 6 
                 MeCN 
                 Xantphos 
                 20.1 
                 74.3 
                 5.6 
               
               
                 7 
                 MeCN 
                 dppf 
                 28.2 
                 69.0 
                 2.8 
               
               
                 8 
                 MeCN 
                 rac- 
                 30.5 
                 64.9 
                 4.6 
               
               
                   
                   
                 BINAP 
               
               
                 9 
                 MeCN 
                 dppp 
                 48.5 
                 40.8 
                 10.7 
               
               
                   
               
            
           
         
       
     
     Example 17 
     Preparation of 2-[(3,5-dichloropyridine-2-carbonyl)amino]acetic acid 
     
       
         
         
             
             
         
       
     
     2,3,5-Trichloropyridine (2.62 g, 14.4 mmol), glycine (1.29 g, 17.2 mmol), dppp (355.2 mg, 0.861 mmol), Pd(OAc)2 (97.0 mg, 0.432 mmol), triethylamine (4.36 g, 43.1 mmol), and acetonitrile (26 mL) were added to a reactor vessel, and the atmosphere of the reaction system was purged with nitrogen and carbon monoxide successively, and pressurized with carbon monoxide at 0.6 MPa, and the resulting mixture was stirred at 110° C. for 24 hours while the pressure of the reaction system was maintained at 0.6 MPa. The progression of reaction was evaluated by HPLC to found that starting materials/desired products=42.3/44.9 (area percentage). 
     Example 18 
     Preparation of ethyl 2-[(3,5-dichloropyridine-2-carbonyl)amino acetate 
     
       
         
         
             
             
         
       
     
     2,3,5-Trichloropyridine (2.62 g, 14.4 mmol), glycine ethyl ester hydrochloride salt (2.40 g, 17.2 mmol), dppp (355.3 mg, 0.861 mmol), Pd(OAc)2 (96.9 mg, 0.432 mmol), triethylamine (4.36 g, 43.1 mmol), and acetonitrile (26 mL) were added to a reactor vessel, and the atmosphere of the reaction system was purged with nitrogen and carbon monoxide successively, and pressurized with carbon monoxide at 0.6 MPa, and the resulting mixture was stirred at 110° C. for 12 hours while the pressure of the reaction system was maintained at 0.6 MPa. The progression of reaction was evaluated by HPLC to found that starting materials/desired products=0.7/82.6 (area percentage). 
     Example 19 
     Preparation of tert-butyl 2-[(3-chloro-5-hydroxypyridine-2-carbonyl)amino]acetate 
     
       
         
         
             
             
         
       
     
     Method A 
     Tert-butyl 2-[(3,5-dichloropyridine-2-carbonyl)amino]acetate (100 mg, 0.328 mmol), Pd catalyst (5 mol %, 0.016 mmol), a ligand (10 mol %, 0.033 mmol), cesium carbonate (235 mg, 0.721 mmol), (E)-benzaldehyde oxime (49 μL, 0.426 mmol), and solvent (1.0 mL) were added to a reactor vessel, the atmosphere of the reaction system was purged with nitrogen, and the mixture was then stirred at 85° C. for 22 hours. The progression of reaction was evaluated by HPLC and the results are shown in Table 2 below. 
     Method B 
     Tert-butyl 2-[(3,5-dichloropyridine-2-carbonyl)amino]acetate (50.4 mg, 0.165 mmol), Pd(OAc) 2  (1.1 mg, 0.0049 mmol), PCy3 (3.3 mg, 0.012 mmol), potassium carbonate (49.9 mg, 0.361 mmol), (E)-benzaldehyde oxime (25 pL, 0.213 mmol), and 2-MeTHF (0.33 mL) were added to a reactor vessel, and the atmosphere of the reaction system was purged with nitrogen, and the mixture was then stirred at 80° C. for 12 hours. The progression of reaction was evaluated by HPLC and the results are shown in Table 2 below. 
     Method C 
     Tert-butyl 2-[(3,5-dichloropyridine-2-carbonyl)amino]acetate (50.0 mg, 0.164 mmol), Pd(OAc) 2  (1.1 mg, 0.0049 mmol), PCy 3  (3.1 mg, 0.011 mmol), tripotassium phosphate (76.5 mg, 0.360 mmol), (E)-benzaldehyde oxime (25 pL, 0.213 mmol), and 2-MeTHF (0.33 mL) were added to a reactor vessel, and the atmosphere of the reaction system was purged with nitrogen, and the mixture was then stirred at 80° C. for 15 hours. The progression of reaction was evaluated by HPLC and the results are shown in Table 2 below. 
     
       
         
           
               
               
               
             
               
                   
                 TABLE 2 
               
             
            
               
                   
                   
               
               
                   
                   
                 HPLC Measurement 
               
               
                   
                 Reaction 
                 Results [area %] 
               
            
           
           
               
               
               
               
               
               
               
               
               
            
               
                   
                   
                   
                   
                   
                 Time 
                 Desired 
                 Starting 
                   
               
               
                 Run 
                 Method 
                 Pd Catalyst, Ligand 
                 Base 
                 Solvent 
                 [h] 
                 Product 
                 Material 
                 Others 
               
               
                   
               
            
           
           
               
               
               
               
               
               
               
               
               
            
               
                 1 
                 A 
                 Pd 2 (dba) 3 , RockPhos 
                 Cs 2 CO 3   
                 DMF 
                 6 
                 23.5 
                 2.4 
                 74.1 
               
               
                   
                   
                   
                   
                   
                 22 
                 21.6 
                 2.4 
                 76.0 
               
               
                 2 
                 A 
                 Pd(OAc) 2 , RockPhos 
                 Cs 2 CO 3   
                 2-MeTHF 
                 6 
                 77.7 
                 4.6 
                 17.7 
               
               
                   
                   
                   
                   
                   
                 22 
                 81.2 
                 n.d. 
                 18.8 
               
               
                 3 
                 A 
                 Pd(PPh 3 ) 4   
                 Cs 2 CO 3   
                 2-MeTHF 
                 6 
                 61.6 
                 2.1 
                 36.3 
               
               
                   
                   
                   
                   
                   
                 22 
                 62.5 
                 n.d. 
                 37.5 
               
               
                 4 
                 A 
                 Pd 2 (dba) 3 , PCy 3   
                 Cs 2 CO 3   
                 2-MeTHF 
                 6 
                 62.7 
                 2.6 
                 34.7 
               
               
                   
                   
                   
                   
                   
                 22 
                 84.9 
                 n.d. 
                 15.1 
               
               
                 5 
                 A 
                 Pd(OAc) 2 , PCy 3   
                 Cs 2 CO 3   
                 2-MeTHF 
                 6 
                 76.8 
                 1.5 
                 21.7 
               
               
                 6 
                 B 
                 Pd(OAc) 2 , PCy 3   
                 K 2 CO 3   
                 2-MeTHF 
                 15 
                 22.3 
                 33.4  
                 44.3 
               
               
                 7 
                 C 
                 Pd(OAc) 2 , PCy 3   
                 K 3 PO 4   
                 2-MeTHF 
                 15 
                 57.2 
                 11.6  
                 31.2 
               
               
                   
               
               
                 Note: 
               
               
                 In Table, “n.d.” represents that no desired products were measured by HPLC. 
               
            
           
         
       
     
     Example 20 
     Preparation of tert-butyl 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl] amino] acetate 
     
       
         
         
             
             
         
       
     
     Tert-butyl 2-[(5-chloro-3-hydroxypyridine-2-carbonyl)amino] acetate (50 mg, 0.174 mmol), Pd catalyst (5 mol %), (3-chlorophenyl)boronic acid (38.2 mg, 0.244 mmol), solvent (1.0 mL), and a base (3.0 eq., 0.523 mmol) were added to a reactor vessel, and the atmosphere of the reaction system was purged with nitrogen, and the mixture was then stirred at 85° C. for 15 hours. The progression of reaction was evaluated by HPLC and the results are shown in Table 3 below. 
     
       
         
           
               
               
             
               
                   
                 TABLE 3 
               
             
            
               
                   
                   
               
               
                   
                 HPLC Measurement 
               
               
                   
                 Results[area %] 
               
            
           
           
               
               
               
               
               
               
               
            
               
                   
                   
                   
                   
                 Desired 
                 Starting 
                   
               
               
                 Run 
                 Pd Catalyst 
                 Base 
                 Solvent 
                 Product 
                 material 
                 Others 
               
               
                   
               
            
           
           
               
               
               
               
               
               
               
            
               
                 1 
                 Pd(PPh) 4   
                 Na 2 CO 3   
                 DME/H 2 O = 3/1 
                 19.4 
                 35.8 
                 44.8 
               
               
                 2 
                 Pd(dppf)Cl 2   
                 K 3 PO 4   
                 1,4-dioxane 
                 12.5 
                 77.0 
                 10.5 
               
               
                 3 
                 Pd 2 (dba) 3 , PCy 3   
                 Cs 2 CO 3   
                 1,4-dioxane 
                 11.2 
                 75.3 
                 13.5 
               
               
                 4 
                 P(tBu) 3 PdG2 
                 Cs 2 CO 3   
                 1,4-dioxane 
                 8.1 
                 73.0 
                 18.9 
               
               
                 5 
                 PdCl 2 (amphos) 2   
                 K 2 CO 3   
                 DME/H 2 O = 3/1 
                 12.1 
                 74.9 
                 13.0 
               
               
                 6 
                 CX22 
                 K 2 CO 3   
                 MeOH 
                 1.4 
                 2.4 
                 96.2 
               
               
                 7 
                 CX22 
                 Cs 2 CO 3   
                 MeOH 
                 n.d. 
                 3.5 
                 96.5 
               
               
                 8 
                 CX22 
                 DBU 
                 MeOH 
                 n.d. 
                 2.2 
                 97.8 
               
               
                 9 
                 CX22 
                 t-BuOK 
                 MeOH 
                 0.7 
                 1.2 
                 98.1 
               
               
                 10 
                 CX22 
                 iPr 2 NEt 
                 MeOH 
                 14.1 
                 72.3 
                 13.6 
               
               
                 11 
                 CX22 
                 iPr 2 NEt 
                 2-PrOH 
                 0.4 
                 90.2 
                 9.4 
               
               
                 12 
                 CX22 
                 iPr 2 NEt 
                 t-BuOH 
                 6.0 
                 84.0 
                 10.0 
               
               
                 13 
                 CX22 
                 iPr 2 NEt 
                 2-PrOH/H 2 O = 3/1 
                 2.8 
                 82.3 
                 14.9 
               
               
                 14 
                 CX22 
                 iPr 2 NEt 
                 DMF/H 2 O = 3/1 
                 n.d. 
                 94.1 
                 5.9 
               
               
                 15 
                 CX22 
                 iPr 2 NEt 
                 THF/H 2 O = 3/1 
                 1.1 
                 91.5 
                 7.4 
               
               
                 16 
                 CX22 
                 iPr 2 NEt 
                 2-MeTHF/H 2 O = 3/1 
                 3.6 
                 83.0 
                 13.4 
               
               
                   
               
               
                 Note: 
               
               
                 In Table, “n.d.” represents that no desired products were measured by HPLC. 
               
            
           
         
       
     
     Example 21 
     Preparation of tert-butyl 2-[[5-(3-chlorophenyl) hydroxypyridine-2-carbonyl] amino] acetate 
     
       
         
         
             
             
         
       
     
     Tert-butyl 2-[(5-chloro-3-hydroxypyridine-2-carbonyl)amino]acetate (100 mg, 0.349 mmol), CX22 (8.5 mg, 0.017 mmol), (3-chlorophenyl)boronic acid (76.4 mg, 0.488 mmol), solvent (2.0 mL), and diisopropyl ethyl amine (0.30 mL, 1.744 mmol) were added to a reactor vessel, and the atmosphere of the reaction system was purged with nitrogen, and the mixture was stirred at 85° C. for 15 hours. The progression of reaction was evaluated by HPLC and the results are shown in Table 4 below. 
     
       
         
           
               
               
               
             
               
                   
                 TABLE 4 
               
             
            
               
                   
                   
               
               
                   
                 HPLC Measurement 
                   
               
               
                   
                 Results [area %] 
               
            
           
           
               
               
               
               
               
            
               
                   
                   
                 Desired 
                 Starting 
                   
               
               
                 Run 
                 Solvent 
                 Product 
                 Material 
                 Others 
               
               
                   
               
               
                 17 
                 MeOH/H 2 O = 3/1 
                 23.2 
                 67.7 
                 9.1 
               
               
                   
               
            
           
         
       
     
     Example 22 
     Preparation of tert-butyl 2-[[5-(3-chlorophenyl) hydroxypyridine-2-carbonyl]amino]acetate 
     
       
         
         
             
             
         
       
     
     Tert-butyl 2-[(5-chloro-3-hydroxypyridine-2-carbonyl)amino]acetate (100 mg, 0.349 mmol), NHC-Pd cat. (5.0 mol %, 0.017 mmol), (3-chlorophenyl)boronic acid (76.4 mg, 0.488 mmol), solvent (2.0 mL), and diisopropyl ethyl amine (0.17 mL, 0.977 mmol) were added to a reactor vessel, and the atmosphere of the reaction system was purged with nitrogen, and the mixture was stirred at 85° C. for 15 hours. The progression of reaction was evaluated by HPLC and the results are shown in Table 5 below. 
     
       
         
           
               
               
               
             
               
                   
                 TABLE 5 
               
             
            
               
                   
                   
               
               
                   
                 Constitute 
                 HPLC Measurement 
               
               
                   
                 ratio of 
                 Results [area %] 
               
            
           
           
               
               
               
               
               
               
            
               
                   
                 NHC-Pd 
                 Solvent 
                 Desired 
                 Starting 
                   
               
               
                 Run 
                 cat. 
                 (Toluene/H 2 O) 
                 Product 
                 Material 
                 Others 
               
               
                   
               
            
           
           
               
               
               
               
               
               
            
               
                 18 
                 CX22 
                 3/1 
                 50.0 
                 36.3 
                 13.7 
               
               
                 19 
                 CX33 
                 3/1 
                 80.9 
                 3.6 
                 15.5 
               
               
                 20 
                 CX31 
                 3/1 
                 68.6 
                 15.5 
                 15.9 
               
               
                 21 
                 CX31 
                 1/1 
                 69.8 
                 12.6 
                 17.6 
               
               
                 22 
                 CX31 
                 1/3 
                 66.1 
                 4.9 
                 29.0 
               
               
                 23 
                 CX21 
                 1/3 
                 66.1 
                 6.3 
                 27.6 
               
               
                   
               
            
           
         
       
     
     Example 23 
     Preparation of 2-chloro-5-(3-chlorophenyl) hydroxypyridine 
     
       
         
         
             
             
         
       
     
     5-bromo-2-chloro-3-hydroxypyridine (7.00 g, 33.583 mmol), Pd(dppf)C12 (36.8 mg, 0.050 mmol), (3-chloropheny)boronic acid (6.30 g, 40.286 mmol), potassium carbonate (6.96 g, 50.358 mmol), tetrahydrofuran (28.0 mL), and water (23.2 mL) were added to a reactor vessel, and the mixture was stirred under reflux under nitrogen atmosphere for 20 hours. The reaction mixture was warmed to 40° C., and water (42.0 mL) and sodium chloride (14.0 g) were added thereto, and the mixture was separated with a separatory funnel to remove the lower layer. Toluene (35.0 mL), water (21.0 mL), and tripotassium phosphate (7.00 g) were added to the mixture, and the mixture was stirred at room temperature, and then separated with a separatory funnel and the lower layer was collected. Water (14.0 mL) and tripotassium phosphate (1.40 g) were added to the upper layer, and the mixture was stirred at room temperature, and separated with a separatory funnel, and the upper layer was removed. The lower layers were combined, and thereto was added sodium chloride (7.00 g), and the mixture was stirred at room temperature, and then separated with a separatory funnel, and the lower layer was removed. The mixture was warmed to 40° C., and water (56.0 mL) was added thereto, and concentrated hydrochloric acid (3.85 g) was added dropwise thereto, and the mixture was cooled to 20° C. The precipitated solid was filtered under reduced pressure, and washed with mixed solution of tetrahydrofuran (3.5 mL) and water (28.0 mL). The mixture was dried under reduced pressure to obtain 2-chloro-5-(3-chlorophenyl)-3-hydroxypyridine (7.34 g) (Yield 91%) 
       1 H NMR (500 MHz, DMSO-d 6 ) δ 10.93 (s, 1H), 8.21 (d, 1H, J =2.3 Hz), 7.74 (t, 1H, J=1.6 Hz), 7.62 (dt, 1H, J=7.4, 1.7 Hz), 7.48-7.55 (m, 3H) 
     Example 24 
     Preparation of ethyl 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetate 
     
       
         
         
             
             
         
       
     
     2-Chloro-5-(3-chlorophenyl)-3-hydroxypyridine (2.50 g, 10.413 mmol), glycine ethyl ester hydrochloride salt (1.53 g, 10.961 mmol), palladium acetate (5.8 mg, 0.026 mmol), 1,4-bis(diphenylphosphino)butane (22.3 mg, 0.052 mmol), tripropylamine (4.48 g, 31.270 mmol), and acetonitrile (30.0 mL) were added to a reactor vessel, and the atmosphere of the reaction system was purged with nitrogen and carbon monoxide successively, and pressurized with carbon monoxide at 0.6 MPa while the pressure of the reaction system was maintained at 0.6 MPa, and the mixture was stirred at 110° C. for 46 hours. The reaction mixture was filtered to remove the solid materials, and washed with acetonitrile (20 mL). The filtrates were concentrated under reduced pressure to 10 mL, and isopropanol (15 mL) was added thereto, and the mixture was heated to be a homogenous solution. After water (10 mL) was added dropwise thereto, the mixture was cooled to 20° C. The precipitated solid was filtered under reduced pressure, and washed with mixed solution of isopropanol (7.5 mL) and water (5 mL). The mixture was dried under reduced pressure to obtain a crude crystal of ethyl 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetate (2.80 g). (Yield 80%) 
     Example 25 
     Purification of ethyl 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetate 
     
       
         
         
             
             
         
       
     
     The crude crystal of ethyl 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetate (5.00 g, 14.936 mmol), N-acetyl L-cysteine (24.4 mg, 0.150 mmol), and mixed solution of isopropanol (35.0 mL) and water (15.0 mL) were added to a reactor vessel, and after the suspension was stirred at 56° C. for 2 hours, the mixture was cooled to 20° C. 
     The solid component was filtered under reduced pressure, and washed with mixed solution of isopropanol (14 mL) and water (6 mL). The mixture was dried under reduced pressure to obtain ethyl 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetate (4.77 g). (Yield 95%) 
       1 H NMR (500 MHz, DMSO-d 6 ) δ 12.30 (s, 1H), 9.50 (t, 1H, J=6.4 Hz), 8.56 (d, 1H, J=2.0 Hz), 7.92-7.95 (m, 1H), 7.77-7.83 (m, 2H), 7.52-7.58 (m, 2H), 4.15 (q, 2H, J=7.1 Hz), 4.09 (d, 2H, J=6.1 Hz), 1.22 (t, 3H, J=7.1 Hz) 
     Example 26 
     Preparation of 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic acid 
     
       
         
         
             
             
         
       
     
     Ethyl 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetate (1.50 g, 4.481 mmol), methyl ethyl ketone (7.5 mL), and activated carbon (75.7 mg) were added to a reactor vessel, and after the mixture was stirred at 50° C. for 2 hours under nitrogen atmosphere, the solid materials were separated by filtration, and washed with methyl ethyl ketone (6.0 mL) to collect filtrates. The resulting mixture was dissolved by adding potassium hydroxide (638.9 mg, 11.201 mmol) and water (6.0 mL), and the above-mentioned filtrates were transferred with methyl ethyl ketone (1.5 mL), and the mixture was stirred at 50° C. for 2 hours to progress the reaction. The reaction mixture was separated with a separatory funnel to remove the upper layer, and tert-butanol (3.75 mL) was added at 40° C. thereto. A solution of 86% Phosphoric acid (1.54 g, 13.441 mmol), sodium chloride (601.1 mg), and water (1.8 mL) was added dropwise to the mixture, and the resulting mixture was stirred at 40° C. for 30 minutes. The mixture was separated with a separatory funnel to remove the lower layer, and water (10.5 mL) was added to the mixture to precipitate the crystal, and the resulting mixture was stirred at 40° C. four 1 hour, and cooled to 5° C. The precipitated materials were filtered under reduced pressure, and washed with mixed solution of tert-butanol (0.75 mL) and water (6.75 mL). The mixture was dried under reduced pressure to obtain 2-[[5-(3-chloropheny)-3-hydroxypyridine-2-carbonyl] amino] acetic acid (1.28 g). (Yield 93%) 
       1 H NMR (500 MHz, DMSO-d 6 ) δ 12.82 (br, 1H), 12.38 (s,  1 H), 9.38 (t, 1H, J=6.1 Hz), 8.55 (d, 1H, J=1.83 Hz), 7.92-7.95 (m, 1H), 7.77-7.83 (m, 2H), 7.52-7.58 (m, 2H), 4.02 (d, 2H, J=6.3 Hz) 
     Example 27 
     Preparation of protected 5-bromo-2-chloro-3-hydroxypyridine 
     
       
         
         
             
             
         
       
     
     5-Bromo-2-chloro-3-hydroxypyridine and the reagents and solvents indicated in Table 6 below were added to a reactor vessel, and the reaction was conducted under the reaction condition shown in Table 6 below while supplementing reagents appropriately. After worked up, the resulting mixture was purified by a silica gel column chromatography to isolate a protected 5-bromo-2-chloro-3-hydroxypyridine. The yield amounts, yield percentages, and MS measurement are shown in 
     Table 7 below. 
     
       
         
           
               
               
               
               
               
             
               
                 TABLE 6 
               
               
                   
               
               
                   
                   
                 5-brmo-2-chloro-3- 
                   
                   
               
               
                 Run 
                 P 1   
                 hydroxy pyridine 
                 Reagents, Solvents 
                 Reaction Condition 
               
               
                   
               
             
            
               
                   
               
            
           
           
               
               
               
               
               
            
               
                 1 
                 Ac 
                 201 mg, 
                 Et 3 N (228 μL, 1.64 mmol) 
                 Reflux at heating, 
               
               
                   
                   
                 0.96 mmo1 
                 Ac 2 O (108 μL, 1.14 mmol) 
                 15 hrs. 
               
               
                   
                   
                   
                 THF (1 L) 
               
               
                 2 
                 Piv 
                 303 mg, 
                 Pyridine (3 mL) 
                 Cool with ice water 
               
               
                   
                   
                 1.45 mmo1 
                 PivCl (210 μL, 1.72 mmol) 
                 bath, 1 hr. 
               
               
                 3 
                 MOM 
                 301 mg, 
                 Acetone (5 mL) 
                 bath temperature 
               
               
                   
                   
                 1.45 mmo1 
                 K 2 CO 3  (303 mg, 2.19 mmol) 
                 60° C., 3 hrs. 
               
               
                   
                   
                   
                 MOMCl (131 μL, 1.72 mmol) 
               
               
                   
                   
                   
                 MOMCl (26 μL, 0.34 mmol) 
                 bath temperature 
               
               
                   
                   
                   
                   
                 60° C., 1 hr. 
               
               
                 4 
                 SEM 
                 300 mg, 
                 t-BuOK (175 mg, 1.56 mmol) 
                 Cool with ice bath, 
               
               
                   
                   
                 1.44 mmo1 
                 THF (2 mL) DMF (2 mL) 
                 1 hr. 
               
               
                   
                   
                   
                 SEMCl (253 μL, 1.44 mmol) 
                 r.t., 2 hrs. 
               
               
                   
                   
                   
                 t-BuOK (175 mg, 1.56 mmol) 
                 Cool with ice water 
               
               
                   
                   
                   
                 SEMCl (253 μL, 1.44 mmol) 
                 bath, 1 hr. 
               
               
                 5 
                 Ts 
                 296 mg, 
                 Acetone (5 mL) 
                 bath temperature 
               
               
                   
                   
                 1.42 mmol 
                 K 2 CO 3  (305 mg, 2.21 mmol) 
                 60° C., 2 hrs. 
               
               
                   
                   
                   
                 TsCl (333 mg, 1.75 mmol) 
               
               
                 6 
                 Ms 
                 300 mg, 
                 Acetone (5 mL) 
                 bath temperature 
               
               
                   
                   
                 1.44 mmol 
                 K 2 CO 3  (301 mg, 2.18 mmol) 
                 60° C., 2 hrs. 
               
               
                   
                   
                   
                 MsCl (134 μL, 1.73 mmol) 
               
               
                 7 
                 Cbz 
                 301 mg, 
                 THF (3 mL) 
                 r.t., 5 hrs. 
               
               
                   
                   
                 1.45 mmol 
                 1 mol/L NaOH aq. (2.2 mL, 
               
               
                   
                   
                   
                 2.2 mmo1) 
               
               
                   
                   
                   
                 CbzCl (297 mg, 1.74 mmol) 
               
               
                   
                   
                   
                 1 mol/L NaOH aq. (2.2 mL, 
                 r.t., 17 hrs. 
               
               
                   
                   
                   
                 2.2 mmol) 
               
               
                   
                   
                   
                 CbzCl (303 mg, 1.78 mmol) 
               
               
                   
                   
                   
                 THF (0.5 mL) 
               
               
                 8 
                 Boc 
                 302 mg, 
                 Boc 2 O (410 mg, 1.88 mmol) 
                 r.t., 25 hrs. 
               
               
                   
                   
                 1.45 mmol 
                 DMAP (18.8 mg, 0.15 mmol) 
               
               
                   
                   
                   
                 Et 3 N (221 μL, 1.59 mmol) 
               
               
                   
                   
                   
                 THF (4 mL) 
               
               
                   
                   
                   
                 Boc 2 O (198 mg, 0.91 mmol) 
                 r.t., 6 hrs. 
               
               
                   
                   
                   
                 Et 3 N (121 μL, 0.87 mmol) 
               
               
                 9 
                 Bn 
                 302 mg, 
                 Acetone (5 mL) 
                 bath temperature 
               
               
                   
                   
                 1.45 mmol 
                 K 2 CO 3  (301 mg, 2.18 mmol) 
                 60° C., 2.5 hrs. 
               
               
                   
                   
                   
                 BnBr (205 μL, 1.73 mmol) 
               
               
                 10 
                 PMB 
                 300 mg, 
                 Acetone (5 mL) 
                 bath temperature 
               
               
                   
                   
                 1.44 mmol 
                 K 2 CO 3  (295 mg, 2.13 mmol) 
                 60° C., 2 hrs. 
               
               
                   
                   
                   
                 KI (27.6 mg, 0.17 mmol) 
               
               
                   
                   
                   
                 PMBCl (235 μL, 1.73 mmol) 
               
               
                 11 
                 Me 
                 401 mg, 
                 Acetone (6.7 mL) 
                 r.t., 8 hrs. 
               
               
                   
                   
                 1.92 mmol 
                 K 2 CO 3  (399 mg, 2.89 mmol) 
               
               
                   
                   
                   
                 MeI (143 μL, 2.30 mmol) 
               
               
                   
                   
                   
                 MeI (60 μL, 0.96 mmol) 
                 r.t., 18 hrs. 
               
               
                 12 
                 Me 2 NCO 
                 297 mg, 
                 Pyridine (3 mL) 
                 Cool with ice water 
               
               
                   
                   
                 1.43 mmol 
                 Me 2 NCOCl (159 μL, 
                 bath, 1.5 hrs., 
               
               
                   
                   
                   
                 1.73 mmol) 
                 r.t., 3.5 hrs 
               
               
                 13 
                 MePhNCO 
                 300 mg, 
                 Pyridine (3 mL) 
                 Cool with ice water 
               
               
                   
                   
                 1.44 mmol 
                 MePhNCOCl (294 mg, 
                 bath, 1 hr., 
               
               
                   
                   
                   
                 1.74 mmol) 
                 r.t., 1 hr. 
               
               
                   
               
            
           
         
       
     
     
       
         
           
               
               
               
               
               
             
               
                 TABLE 7 
               
               
                   
               
               
                   
                   
                   
                 Yield 
                 MS Measurement 
               
               
                 Run 
                 P 1   
                 Yields 
                 Percentages 
                 Result 
               
               
                   
               
             
            
               
                   
               
            
           
           
               
               
               
               
               
            
               
                 1 
                 Ac 
                 222 mg 
                 93% 
                 m/z = 249.90 
               
               
                 2 
                 Piv 
                 388 mg 
                 92% 
                 m/z = 292.36 
               
               
                 3 
                 MOM 
                 336 mg 
                 92% 
                 m/z = 252.36 
               
               
                 4 
                 SEM 
                 496 mg 
                 quant. 
                 m/z = 338.23 
               
               
                 5 
                 Ts 
                 503 mg 
                 98% 
                 m/z = 362.24 
               
               
                 6 
                 Ms 
                 370 mg 
                 90% 
                 m/z = 286.29 
               
               
                 7 
                 Cbz 
                 413 mg 
                 77% 
                 m/z = 342.23 
               
               
                 8 
                 Boc 
                 350 mg 
                 79% 
                 m/z = 308.05 
               
               
                 9 
                 Bn 
                 412 mg 
                 97% 
                 m/z = 298.03 
               
               
                 10 
                 PMB 
                 436 mg 
                 92% 
                 m/z = 328.23 
               
               
                 11 
                 Me 
                 345 mg 
                 81% 
                 m/z = 222.37 
               
               
                 12 
                 Me 2 NCO 
                 383 mg 
                 96% 
                 m/z = 279.41 
               
               
                 13 
                 MePhNCO 
                 490 mg 
                 99% 
                 m/z = 341.19 
               
               
                   
               
            
           
         
       
     
     Example 28 
     Preparation of protected 5-(3-chlorophenyl)-2-chloro-3-hydroxypyridine 
     
       
         
         
             
             
         
       
     
     The protected 5-bromo-2-chloro-3-hydroxypyridine, (3-chlorophenyl)boronic acid, solvent, Pd(dppf)C12 (0.03 equivalent amounts relative to the protected 5-bromo-2-chloro-3-hydroxypyridine), potassium carbonate (1.2 equivalent amounts relative to the protected 5-bromo-2-chloro-3-hydroxypyridine) each in the amounts shown in Table 8 below were added to a reactor vessel, and the mixture was stirred appropriately under reflux at heating under nitrogen atmosphere, and the reaction was conducted for the time shown in Table 8 below while supplementing (3-chloropheny)boronic acid. After worked up, the resulting mixture was purified by silica gel column chromatography to isolate the protected 5-(3-chlorophenyl)-2-chloro-3-hydroxypyridine. The yield amounts, yield percentages, and MS measurement results were shown in Table 9 below. 
     
       
         
           
               
               
               
               
               
               
             
               
                 TABLE 8 
               
               
                   
               
               
                   
                   
                 Protected 5-bromo-2- 
                 (3-Chloropheny1) 
                   
                 Reaction 
               
               
                 Run 
                 P 1   
                 chloro-3-hydroypyridine 
                 boronic acid 
                 Solvent 
                 Time 
               
               
                   
               
             
            
               
                   
               
            
           
           
               
               
               
               
               
               
            
               
                 1 
                 Ac 
                 222 mg, 0.89 mmol 
                 151 mg, 0.96 mmol 
                 THF (1.2 mL) 
                 3 hrs. 
               
               
                   
                   
                   
                   
                 Water (0.6 mL) 
               
               
                 2 
                 Piv 
                 388 mg, 1.33 mmol 
                 218 mg, 1.39 mmol 
                 THF (1.8 mL) 
                 3.5 hrs.   
               
               
                   
                   
                   
                 42 mg, 0.27 mmol 
                 Water (0.9 mL) 
                 1.5 hrs.   
               
               
                 3 
                 MOM 
                 336 mg, 1.33 mmol 
                 261 mg, 1.67 mmol 
                 THF (1.8 mL) 
                 18.5 hrs.   
               
               
                   
                   
                   
                   
                 Water (0.9 mL) 
               
               
                 4 
                 SEM 
                 496 mg, 1.44 mmol 
                 228 mg, 1.46 mmol 
                 THF (2.0 mL) 
                 4 hrs. 
               
               
                   
                   
                   
                 23 mg, 0.14 mmo1 
                 Water (1.0 mL) 
                 2 hrs. 
               
               
                 5 
                 Ts 
                 503 mg, 1.39 mmol 
                 242 mg, 1.64 mmol 
                 THF (2.0 mL) 
                 3 hrs. 
               
               
                   
                   
                   
                   
                 Water (1.0 mL) 
               
               
                 6 
                 Ms 
                 370 mg, 1.29 mmol 
                 224 mg, 1.43 mmol 
                 THF (1.86 mL) 
                 4 hrs. 
               
               
                   
                   
                   
                   
                 Water (0.93 mL) 
               
               
                 7 
                 Cbz 
                 380 mg, 1.11 mmol 
                 193 mg, 1.24 mmol 
                 THF (1.6 mL) 
                 3 hrs. 
               
               
                   
                   
                   
                   
                 Water (0.8 mL) 
               
               
                 8 
                 Boc 
                 350 mg, 1.14 mmol 
                 197 mg, 1.26 mmol 
                 THF (1.64 mL) 
                 3 hrs. 
               
               
                   
                   
                   
                   
                 Water (0.82 mL) 
               
               
                 9 
                 Bn 
                 421 mg, 1.41 mmol 
                 243 mg, 1.55 mmol 
                 THF (2.0 mL) 
                 4 hrs. 
               
               
                   
                   
                   
                   
                 Water (1.0 mL) 
               
               
                 10 
                 PMB 
                 436 mg, 1.33 mmol 
                 229 mg, 1.46 mmol 
                 THF (1.9 mL) 
                 22.5 hrs.   
               
               
                   
                   
                   
                   
                 Water (0.945 mL) 
               
               
                 11 
                 Me 
                 345 mg, 1.55 mmol 
                 268 mg, 1.72 mmol 
                 THF (2.2 mL) 
                 7 hrs. 
               
               
                   
                   
                   
                   
                 Water (1.1 mL) 
               
               
                 12 
                 Me 2 NCO 
                 382 mg, 1.37 mmol 
                 236 mg, 1.51 mmol 
                 THF (1.8 mL) 
                 4 hrs. 
               
               
                   
                   
                   
                   
                 Water (0.945 mL) 
               
               
                 13 
                 MePhNCO 
                 485 mg, 1.42 mmol 
                 246 mg, 1.57 mmol 
                 THF (2.0 mL) 
                 5 hrs. 
               
               
                   
                   
                   
                   
                 Water (1.0 mL) 
               
               
                   
               
            
           
         
       
     
     
       
         
           
               
               
               
               
               
             
               
                 TABLE 9 
               
               
                   
               
               
                   
                   
                   
                 Yield 
                 MS Measurement 
               
               
                 Run 
                 P 1   
                 Yields 
                 percentages 
                 Results 
               
               
                   
               
             
            
               
                   
               
            
           
           
               
               
               
               
               
            
               
                 1 
                 Ac 
                 196 mg 
                 79% 
                 m/z = 282.03 
               
               
                 2 
                 Piv 
                 417 mg 
                 96% 
                 m/z = 324.36 
               
               
                 3 
                 MOM 
                 374 mg 
                 99% 
                 m/z = 284.36 
               
               
                 4 
                 SEM 
                 470 mg 
                 88% 
                 m/z = 370.30 
               
               
                 5 
                 Ts 
                 486 mg 
                 89% 
                 m/z = 394.25 
               
               
                 6 
                 Ms 
                 422 mg 
                 97% 
                 m/z = 318.23 
               
               
                 7 
                 Cbz 
                 309 mg 
                 69% 
                 m/z = 374.33 
               
               
                 8 
                 Boc 
                 360 mg 
                 93% 
                 m/z = 340.12 
               
               
                 9 
                 Bn 
                 447 mg 
                 96% 
                 m/z = 330.12 
               
               
                 10 
                 PMB 
                 452 mg 
                 95% 
                 m/z = 360.38 
               
               
                 11 
                 Me 
                 378 mg 
                 96% 
                 m/z = 254.44 
               
               
                 12 
                 Me 2 NCO 
                 451 mg 
                 quant. 
                 m/z = 311.36 
               
               
                 13 
                 MePhNCO 
                 547 mg 
                 98% 
                 m/z = 373.05 
               
               
                   
               
            
           
         
       
     
     Example 29 
     Preparation of ethyl [[3-benzyloxy-5-(3-chlorophenyl)pyridine-2-carbonyl] amino] acetate 
     
       
         
         
             
             
         
       
     
     3-(Benzyloxy)-2-chloro-5-(3-chlorophenyl)pyridine (200 mg, 0.61 mmol), acetonitrile (3 mL), glycine ethyl ester hydrochloride salt (95 mg, 0.68 mmol), triethylamine (255 pL, 1.83 mmol), 1,3-bis(diphenylphosphino)propane (14.7 mg, 0.03 mmol), and palladium acetate (5.0 mg, 0.02 mmol) were added to a reactor vessel, and the atmosphere of the reaction system was purged with nitrogen and carbon monoxide successively, and pressurized with carbon monoxide at 0.6 MPa while the pressure of the reaction system was maintained at 0.6 MPa, and the mixture was stirred at 110° C. for 23 hours. Ethyl acetate was added thereto and the precipitated solid was separated by filtration, and washed with ethyl acetate. The filtrates were concentrated and the resulting residue was purified by a silica gel column chromatography to obtain ethyl 2-[[3-benzyloxy-5-(3-chlorophenyl)pyridine-2-carbonyl]amino]acetate (209 mg). (Yield 75%) 
       1 H NMR (CDCl 3 ) δ :1.31 (3H, t, J=7.2 Hz), 4.22-4.28 (4H, m), 5.34 (2H, s), 7.32-7.35 (1H, m), 7.39-7.43 (5H, m), 7.48-7.50 (2H, m), 7.53-7.55 (2H, m), 8.31 (1H, t, J=4.8 Hz), 8.43 (1H, d, J=1.6 Hz). 
     Example 30 
     Preparation of ethyl 2-[[5-(3-chlorophenyl)-3-[(4-methoxyphenyl)methoxy]pyridine-2-carbonyl]amino]acetate 
     
       
         
         
             
             
         
       
     
     2-Chloro-5-(3-chlorophenyl)-3-[(4-methoxyphenyl)methoxy]pyridine (201 mg, 0.56 mmol), acetonitrile (3.0 mL), glycine ethyl ester hydrochloride salt (88 mg, 0.64 mmol), triethylamine (234 pL, 1.68 mmol), 1,3-bis(diphenylphosphino)propane (15.0 mg, 0.04 mmol), and palladium acetate (4.2 mg, 0.02 mmol) were added to a reactor vessel, and the atmosphere of the reaction system was purged with nitrogen and carbon monoxide successively, and pressurized with carbon monoxide at 0.6 MPa while the pressure of the reaction system was maintained at 0.6 MPa, and the mixture was stirred at 110° C. for 15 hours. Ethyl acetate was added thereto and the precipitated solid was separated by filtration, and washed with ethyl acetate. The filtrates were concentrated and the resulting residue was purified by a silica gel column chromatography to obtain ethyl 2-[[5-(3-chlorophenyl)-3-[(4-methoxyphenyl)methoxy]pyridine-2-carbonyl]amino]acetate (191 mg). (Yield 73%) 
       1 H NMR (CDCl 3 ) δ : 1.30 (3H, t, J=7.2 Hz), 3.81 (3H, s), 4.18-4.27 (4H, m), 5.27 (2H, s), 6.93 (2H, d, J=8.8 Hz), 7.41-7.51 (7H, m), 8.30 (1H, t, J=5.2 Hz), 8.43 (1H, d, J =2.0 Hz). 
     Example 31 
     Preparation of 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic acid 
     
       
         
         
             
             
         
       
     
     Ethyl 2-[[3-benzyloxy-5-(3-chlorophenyl)pyridine-2-carbonyl]amino]acetate (170 mg, 0.40 mmol), dichloromethane (5 mL), hydrogen bromide (30% acetic solution) (1 mL) were added to a reactor vessel, and the mixture was stirred at 40° C. for 24 hours. The reaction mixture was cooled under ice-cooling, and thereto was added water, and the mixture was extracted with dichloromethane three times. The organic layers were combined, and dried over sodium sulfate, and the solid was then separated by filtration. The filtrates were concentrated under reduced pressure, and thereto was further added toluene, and the resulting mixture was concentrated under reduced pressure again. The concentrated residue was purified by a silica gel column chromatography to obtain 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic acid (37 mg). (Yield 30%) 
       1 H NMR (DMSO-d 6 ) δ : 3.93 (2H, d, J=5.6 Hz), 7.52-7.57 (2H, m), 7.78 (1H, d, J=2.0 Hz), 7.79-7.81 (1H, m), 7.92-7.93 (1H, m), 8.54 (1H, d, J=2.0 Hz), 9.27 (1H, t, J=5.6 Hz), 12.41-12.49 (1H, br). 
     Example 32 
     Preparation of ethyl 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetate 
     
       
         
         
             
             
         
       
     
     Ethyl 2-[[5-(3-chlorophenyl)-3-[(4-methoxypheny) methoxy] pyridine-2-carbonyl ] amino] acetate (163 mg, 0.36 mmol), dichloromethane (10 mL), hydrogen bromide (30% acetic solution) (1 mL) were added to a reactor vessel, and the mixture was stirred at 40° C. for 2 hours. The reaction mixture was cooled under ice-cooling, and thereto was added saturated hydrogen carbonate solution, and the mixture was extracted with dichloromethane twice. The organic layers were combined, and the mixture was dried over sodium sulfate, and the solid was separated by filtration, and the filtrates were concentrated under reduced pressure. After the concentrated residue was purified by a silica gel column chromatography, the resulting mixture was further purified by an amino silica gel column chromatography to obtain a crude product. The crude product was purified by a reverse silica gel column to obtain ethyl 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetate (84 mg). (Yield 68%) 
       1 H NMR (CDCl 3 ) δ : 1.33 (3H, t, J=7.2 Hz), 4.24-4.31 (4H, m), 7.41-7.49 (4H, m), 7.57-7.58 (1H, m), 8.30 (1H, d, J=2.0 Hz), 8.42 (1H, br), 11.8 (1H, s). 
     Example 33 
     Preparation of 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic acid 
     
       
         
         
             
             
         
       
     
     Ethyl 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetate (76 mg, 0.22 mmol), tetrahydrofuran (0.71 mL), and 1 mol/L aqueous sodium hydroxide solution (0.7 mL, 0.7 mmol) were added to a reactor vessel, and the mixture was stirred at room temperature for 2 hours. The reaction mixture was neutralized with 1 mol/L hydrochloric acid (0.8 mL, 0.8 mmol), and adjusted with 1 mol/L aqueous sodium hydroxide solution to around pH 2. The mixture was concentrated under reduced pressure to distill the solvent, and the precipitated solid was filtered under reduced pressure, and washed with water. The mixture was dried under reduced pressure to obtain 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino] acetic acid (64 mg). (Yield 95%) 
       1 H NMR (DMSO-d 6 ) δ : 3.94 (2H, d, J=6.0 Hz), 7.52-7.57 (2H, m), 7.78 (1H, d, J=1.6 Hz), 7.79-7.81 (1H, m), 7.92-7.93 (1H, m), 8.55 (1H, d, J=1.6 Hz), 9.28 (1H, t, J=6.0 Hz), 12.4-12.5 (1H, br). 
     Example 34 
     Preparation of 2-[[3-chloro-5-(3-chlorophenyl)pyridine-2-carbonyl]amino]acetic acid 
     
       
         
         
             
             
         
       
     
     According to the methods described in the Patent Literature 2, 3,5-dichloropyridine-2-carbonitrile (13.50 g, 86.33 mmol), (3-chlorophenyl)boronic acid (15.68 g, 90.64 mmol), potassium carbonate (14.32 g, 103.62 mmol), dimethyl formamide (85 mL), water (10 mL), Pd(dppf)C12 (316 mg, 0.43 mmol), and dimethyl formamide (4.3 mL) were added sequentially to a reactor vessel, and the mixture was subjected to a reaction at 50° C. (bath temperature) under nitrogen atmosphere for 19 hours. The worked up procedure was conducted to obtain 3-chloro-5-(3-chlorophenyl)pyridine-2-carbonitrile (21.51 g). (Yield quant.) 
     3-Chloro-5-(3-chlorophenyl)pyridine-2-carbonitrile (30.70 g, 123.25 mmol), ethanol (153 mL), and 1 mol/L aqueous sodium hydroxide solution (271 mL, 271 mmol) were added to a reactor vessel, and the mixture was subjected to a reaction at 80° C. (bath temperature) for 26 fours. The worked up procedure was conducted to obtain 3-chloro-5-(3-chlorophenyl)pyridine-2-carboxylic acid (33.83 g). (Yield quant.) 
     3-Chloro-5-(3-chlorophenyl)pyridine-2-carboxylic acid (33.83 g), dimethyl formamide (352 mL), glycine methyl ester hydrochloride salt (20.12 g, 160.25 mmol), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride salt (EDC.HC1) (35.44 g, 184.87 mmol), 1-hydroxybenzotriazole monohydrate (HOBt-H20) (25.00 g, 185.00 mmol), and diisopropyl ethyl amine (85 mL, 493.23 mmol) were added to a reactor vessel, and the mixture was subjected to a reaction at room temperature for 15 hours. The worked up procedure was conducted to obtain methyl 2-[[3-chloro-5-(3-chlorophenyl)pyridine-2-carbonyl]amino]acetate (32.63 g). (Yield 78.1%) 
     Methyl 2-[[3-chloro-5-(3-chlorophenyl)pyridine-2-carbonyl]amino]acetate (32.67 g, 99.27 mmol), 2 mol/L aqueous sodium hydroxide solution (168 mL, 336 mmol), and water (96 mL) were added to a reactor vessel, and the mixture was subjected to a reaction at 50° C. (bath temperature) for 3 hours. After cooled to room temperature, the mixture was adjusted with hydrochloric acid to pH 4. The precipitated materials were filtered and dried to obtain 2-[[3-chloro-5-(3-chlorophenyl)pyridine-2-carbonyl]amino]acetic acid (32,19 g). Yield (99.7%) 
       1 H NMR (DMSO-d 6 ) δ 3.95 (2H, d, J=6.0 Hz), 7.54-7.59 (2H, m), 7.82-7.87 (1H, m), 7.98-7.99 (1H, m), 8.43 (1H, d, J=2.0 Hz), 8.93-8.96 (2H, m), 12.71 (1H, br). 
     In a two dimensional NMR, a NOESY correlation between protons at 4-position and 6-position of the pyridine ring and proton of the chlorophenyl group was found. It was decided from this event that the obtained compound was the present isomer. 
     Example 35 
     Preparation of methyl 2-[[5-chloro-3-(3-chlorophenyl)pyridine-2-carbonyl]amino]acetate 
     
       
         
         
             
             
         
       
     
     Methyl 2-[(3,5-dichloropyridine-2-carbonyl)amino]acetate (1.00g, 3.80 mmol), (3-chlorophenyl)boronic acid (595.9 mg, 3.81 mmol), and dimethyl formamide (8.0 mL) were added to a reactor vessel, and the atmosphere of the reaction system was purged with nitrogen. A solution of potassium carbonate (1.05 g, 7.60 mmol) and water (1.0 mL), Pd(dppf)C12 (278.4 mg, 0.38 mmol), and dimethyl formamide (2.0 mL) were added to the mixture, and the atmosphere of the reaction system was purged with nitrogen again, and the mixture was then subjected to a reaction at 47° C. for 16 hours. After the reaction mixture was concentrated under reduced pressure, the mixture was extracted with ethyl acetate and water, and the organic layer was concentrated under reduced pressure. Methanol was added to the concentrated residue, and the solid component was separated by filtration, and the filtrates were concentrated under reduced pressure. The concentrated residue was purified by a column chromatography to obtain methyl 2-[[5-chloro-3-(3-chlorophenyl)pyridine-2-carbonyl]amino]acetate (45 mg). (Yield 3.5%) 
     MS : m/z=339/341 
     Example 36 
     Preparation of methyl 2-[[5-chloro-3-(3-chlorophenyl)pyridine-2-carbonyl]amino]acetate and 2-[[5-chloro-3-(3-chlorophenyl)pyridine-2-carbonyl]amino]acetic acid 
     
       
         
         
             
             
         
       
     
     Methyl 2-[(3,5-dichloropyridine-2-carbonyl)amino]acetate (1.01g, 3.84 mmol), (3-chlorophenyl)boronic acid (1.18 g, 7.55 mmol), potassium carbonate (0.51 g, 3.69 mmol), CX32 (127.6 mg, 0.20 mmol), and methanol (3.0 mL) were added to a reactor vessel, and the atmosphere of the reaction system was purged with nitrogen, and the mixture was subjected to a reaction at 60° C. for 21 hours. The reaction mixture was extracted with 2 mol/L hydrochloric acid (10 mL) and ethyl acetate (20 mL), and the organic layer was dried over magnesium sulfate, and then concentrated under reduced pressure. The concentrated residue was purified by a column chromatography to obtain methyl 2-[[5-chloro-3-(3-chlorophenyl)pyridine-2-carbonyl]amino]acetate (559 mg) and 2-[[5-chloro-3-(3-chlorophenyl)pyridine-2-carbonyl]amino]acetic acid (110 mg). 
     Preparation of methyl 2-[[5-chloro-3-(3-chlorophenyl)pyridine-2-carbonyl]amino]acetate Yield 43% 
     Preparation of 2-[[5-chloro-3-(3-chlorophenyl)pyridine group-2-carbonyl] amino] acetic acid 
     Yield 9% 
       1 H NMR (CDCl 3 ): δ 8.55 (d, J=2.3 Hz, 1H), 8.25 (t, J=5.6 Hz, 1H), 7.68 (d, J=2.2 Hz, 1H), 7.37 (dt, J=8.1, 1.7 Hz, 1H), 7.33 (t, J=7.7 Hz, 1H), 7.29 (t, J=1.6 Hz, 1H), 7.19 (dt, J=7.4, 1.5 Hz, 1H), 4.18 (d, J=5.7 Hz, 2H). 
     In a two dimensional NMR, a NOESY correlation between proton at 4-position of the pyridine ring and proton of the chlorophenyl group was found, while a NOESY correlation between proton at 6-position of the pyridine ring and proton of the chlorophenyl group was not found. It was decided from this event that the obtained compound was the present isomer. 
     Example 37 
     Preparation of 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]ethyl acetate (I type crystal form) 
     
       
         
         
             
             
         
       
     
     2-Chloro-5-(3-chlorophenyl)-3-hydroxy pyridine (4.00 g, 16.661 mmol), glycine ethyl ester hydrochloride salt (2.44 g, 17.481 mmol), palladium acetate (9.4 mg, 0.042 mmol), 1,4-bis(diphenylphosphino)butane (35.8 mg, 0.084 mmol), tripropylamine (7.16 g, 49.976 mmol), sodium propionate (160.2 mg, 1.666 mmol), and acetonitrile (48 mL) were added to a reactor vessel, and the atmosphere of the reaction system was purged with nitrogen and carbon monoxide successively, and pressurized with carbon monoxide at 0.6 MPa while the pressure of the reaction system was maintained at 0.6 MPa, and the mixture was stirred at 110° C. for 18 hours. The reaction mixture was filtered to remove the solid materials and washed with acetonitrile (32 mL). 
     Separately, 2-chloro-5-(3-chlorophenyl)-3-hydroxypyridine (4.00 g, 16.661 mmol), glycine ethyl ester hydrochloride salt (2.44 g, 17.481 mmol), palladium acetate (9.4 mg, 0.042 mmol), 1,4-bis(diphenylphosphino)butane (35.6 mg, 0.083 mmol), tripropylamine (7.15 g, 49.906 mmol), and acetonitrile (48 mL) were added to a reactor vessel, and the atmosphere of the reaction system was purged with nitrogen and carbon monoxide successively, and pressurized with carbon monoxide at 0.6 MPa while the pressure of the reaction system was maintained at 0.6 MPa, and the mixture was stirred at 110° C. for 46 hours. The reaction mixture was filtered to remove the solid materials, and washed with acetonitrile (32 mL). The filtrates were concentrated under reduced pressure to 16 mL. 
     Separately, 2-chloro-5-(3-chlorophenyl)-3-hydroxypyridine (4.00 g, 16.661 mmol), glycine ethyl ester hydrochloride salt (2.44 g, 17.481 mmol), palladium acetate (9.4 mg, 0.042 mmol), 1,4-bis(diphenylphosphino)butane (71.1 mg, 0.167 mmol), tripropylamine (7.16 g, 49.976 mmol), and acetonitrile (48 mL) were added to a reactor vessel, and the atmosphere of the reaction system was purged with nitrogen and carbon monoxide successively, and pressurized with carbon monoxide at 0.6 MPa while the pressure of the reaction system was maintained at 0.6 MPa, and the mixture was stirred at 110° C. for 46 hours. The reaction mixture was filtered to remove the solid materials, and washed with acetonitrile (32 mL). 
     The mixture composed of three parts of the reaction were combined, and the half of the solutions were concentrated under reduced pressure to 24 mL. Isopropanol (36 mL) was added thereto, and the mixture was dissolved by heating at 65° C., and water (12 mL) was added thereto, and the mixture was stirred at 50° C. Water (24 mL) was added dropwise thereto, and the resulting mixture was heated to 65° C. and stirred, and then cooled to 30° C. The precipitated solid was filtered under reduced pressure, and washed with mixed solution of isopropanol (18 mL) and water (12 mL). The mixture was dried under reduced pressure to obtain an I type crystal of 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]ethyl acetate (5.99 g). (Yield 72%) 
     An X-ray crystallographic analysis was conducted on the obtained I type crystal under the conditions below.
     Powder X-ray crystallographic analysis condition   Device: MiniFlex600 (Rigaku)   Operating condition;   

     X ray output: Cu-Ka, Tube voltage: 40 kV, Tube current: 15 mA, Sampling range: 0.02° 
     Scan range: 3° to 40° 
     Measured Temperature: Room Temperature 
     A XRD diffraction pattern of the I type crystal is shown in  FIG.  1   . Also the diffraction angle (20) value of the
     I type crystal is shown in Table 10.   

     
       
         
           
               
               
               
             
               
                   
                 TABLE 10 
               
               
                   
                   
               
               
                   
                 Peak No. 
                 2θ (°) 
               
               
                   
                   
               
             
            
               
                   
               
            
           
           
               
               
               
            
               
                   
                 1 
                 5.72 
               
               
                   
                 2 
                 7.96 
               
               
                   
                 3 
                 11.04 
               
               
                   
                 4 
                 11.82 
               
               
                   
                 5 
                 14.14 
               
               
                   
                 6 
                 14.54 
               
               
                   
                 7 
                 15.08 
               
               
                   
                 8 
                 15.94 
               
               
                   
                 9 
                 17.74 
               
               
                   
                 10 
                 18.20 
               
               
                   
                 11 
                 20.40 
               
               
                   
                 12 
                 20.78 
               
               
                   
                 13 
                 24.10 
               
               
                   
                 14 
                 24.68 
               
               
                   
                 15 
                 25.10 
               
               
                   
                 16 
                 26.82 
               
               
                   
                 17 
                 39.22 
               
               
                   
                   
               
            
           
         
       
     
     The I type crystal of the compound (a3-1-A) of the present invention can be characterized by having one or more of the below-mentioned characteristic peaks in the powder X ray diffraction pattern.
     (1) The crystal has preferably the substantially-identical patterns to the powder X ray diffraction pattern indicated in  FIG.  1   .   (2) Examples of the characteristic patterns in the powder X ray diffraction patterns of the I type crystal include as the diffraction angles expressed as 20, 7.96° ±0.2°, 11.82° ±0.2°, 14.14° ±0.2°, and/or 15.94° ±0.2°. Examples of another characteristic peaks include 14.54° ±0.2°, 15.08° ±0.2°, 24.10° ±0.2°, 24.68°±0.2°, and/or 26.82° ±0.2°. Examples of the other characteristic peaks include 5.72° ±0.2°, 11.04°±0.2°, 17.74°±0.2°, 18.20 0 ±0.2 0 , 20.40° ±0.2°, 20.78°±0.2°, 25.10°±0.2°, and/or 39.22° ±0.2°.   

     Example 38 
     Preparation of ethyl 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetate (II type crystal form) 
     
       
         
         
             
             
         
       
     
     2-Chloro-5-(3-chlorophenyl)-3-hydroxypyridine (4.00 g, 16.661 mmol), glycine ethyl ester hydrochloride salt (2.44 g, 17.481 mmol), palladium acetate (9.3 mg, 0.041 mmol), 1,4-bis(diphenylphosphino)butane (35.6 mg, 0.083 mmol), tripropylamine (11.94 g, 83.339 mmol), and acetonitrile (48 mL) were added to a reactor vessel, and the atmosphere of the reaction system was purged with nitrogen and carbon monoxide successively, and pressurized with carbon monoxide at 0.6 MPa while the pressure of the reaction system was maintained at 0.6 MPa, and the mixture was stirred at 110° C. for 46 hours. The reaction mixture was filtered to remove the solid materials, and washed with acetonitrile (32 mL). The filtrates were concentrated under reduced pressure to 12 mL, and transferred with acetonitrile (4 mL). Isopropanol (24 mL) was added dropwise thereto, and the mixture was stirred at 35° C., and after water (16 mL) was added dropwise thereto, the mixture was stirred at 30° C. Water (8 mL) was added dropwise thereto, and the mixture was stirred at 30° C., and the precipitated solid was then filtered under reduced pressure, and washed with mixed solution of isopropanol (12 mL) and water (8 mL). The mixture was dried under reduced pressure to obtain II type of crystal of ethyl 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetate (3.61 g). (Yield 65%) 
     An X-ray crystallographic analysis was conducted on the obtained II type crystal under the conditions below. 
     Powder X-ray crystallographic analysis condition
     Device: MiniFlex600 (Rigaku)   Operating condition;   

     X ray output: Cu-Ka, Tube voltage: 40 kV, Tube current: 15 mA, Sampling range: 0.02° 
     Scan range: 3° to 40° 
     Measured Temperature: Room Temperature 
     A XRD diffraction pattern of the II type crystal is shown in  FIGS.  2  and  3   . Also the diffraction angle (20) value of the II type crystal is shown in Table 11. 
     
       
         
           
               
               
               
             
               
                   
                 TABLE 11 
               
               
                   
                   
               
               
                   
                 Peak No. 
                 2θ (°) 
               
               
                   
                   
               
             
            
               
                   
               
            
           
           
               
               
               
            
               
                   
                 1 
                 5.64 
               
               
                   
                 2 
                 8.52 
               
               
                   
                 3 
                 10.78 
               
               
                   
                 4 
                 16.98 
               
               
                   
                 5 
                 17.66 
               
               
                   
                 6 
                 18.08 
               
               
                   
                 7 
                 18.66 
               
               
                   
                 8 
                 20.16 
               
               
                   
                 9 
                 20.60 
               
               
                   
                 10 
                 21.34 
               
               
                   
                 11 
                 22.64 
               
               
                   
                 12 
                 23.56 
               
               
                   
                 13 
                 25.08 
               
               
                   
                 14 
                 26.12 
               
               
                   
                 15 
                 29.90 
               
               
                   
                 16 
                 34.34 
               
               
                   
                   
               
            
           
         
       
     
     The II type crystal of the compound (a3-1-A) of the present invention can be characterized by having one or more of the below-mentioned characteristic peaks in the powder X ray diffraction pattern.
     (1) The crystal has preferably the substantially-identical patterns to the powder X ray diffraction pattern indicated in  FIG.  2    and/or  FIG.  3   .   (2) Examples of the characteristic patterns in the powder   

     X ray diffraction patterns of the II type crystal include as the diffraction angles expressed as 20, 8.52° ±0.2°, 16.98°±0.2°, 20.16°±0.2°, and/or 26.12°±0.2°. Examples of another characteristic peaks include 10.78° ±0.2°, 23.56° ±0.2°, 29.90 0 ±0.2 0 , and/or 34.34° ±0.2°. Examples of the other characteristic peaks include 5.64° ±0.2°, 17.66° ±0.2°, 18.08° ±0.2°, 18.66° ±0.2°, 20.60° ±0.2°, 21.34±0.2°, 22.64° ±0.2°, and/or 25.08° ±0.2°. 
     Example 39 
     Preparation of 2-chloro-5-(3-chlorophenyl)-3-hydroxypyridine 
     
       
         
         
             
             
         
       
     
     2,2-Dimethyl [2-chloro-5-(3-chlorophenyl)-3-pyridyl]propionate (99.9 mg, 0.308 mmol), methanol (1.03 mL), and 8 mol/L aqueous sodium hydroxide solution (0.116 mL) were added to a reactor vessel, and the mixture was stirred at room temperature for 1.5 hours, and then raised to 40° C. and stirred for additional three hours. 8 mol/L Aqueous sodium hydroxide solution (0.116 mL) was added thereto, and the mixture was stirred at 40° C. for 1.5 hours, and it was confirmed a disappearance of the starting material. The reaction mixture was adjusted with 6 mol/L hydrochloric acid to around pH 3, and water was further added thereto, and the mixture was extracted with chloroform three times. The organic layers were combined, dried over sodium sulfate, and concentrated to dryness to obtain a crude product. This crude product was purified by a silica gel column chromatography to obtain 2-chloro-5-(3-chlorophenyl)-3-hydroxy pyridine (68.7 mg). (Yield 92%) IH NMR (CDCl 3 ) δ : 5.70 (1H, brs), 7.38-7.45 (3H, m), 7.50(1H, d, J=2.3 Hz), 7.53-7.54 (1H, m), 8.19 (1H, d, J=2.1 Hz). 
     Example 40 
     Preparation of 2-chloro-5-(3-chlorophenyl)-3-hydroxypyridine 
     
       
         
         
             
             
         
       
     
     [2-Chloro-5-(3-chlorophenyl)-3-pyridyl]methane sulfonate (504.1 mg, 1.584 mmol), methanol (5.20 mL), and 8 mol/L aqueous sodium hydroxide solution (0.99 mL) were added to a reactor vessel, and the mixture was stirred at 40° C. for 13 hours. After it was confirmed the disappearance of [2-chloro-5-(3-chlorophenyl)-3-pyridyl]methane sulfonate, the reaction mixture was adjusted with 6 mol/L hydrochloric acid to around pH 3, and water was further added thereto, and the mixture was extracted with chloroform three times. The organic layers were combined, and the mixture was dried over sodium sulfate, and then concentrated to dryness to obtain a crude product. The crude product was purified by a silica gel column chromatography to obtain 2-chloro-5-(3-chloropheny)-3-hydroxypyridine (380.3 mg). (Yield 92%) 
       1 H NMR (CDCl 3 ) δ : 5.69 (1H, brs), 7.38-7.45 (3H, m), 7.50 (1H, d, J=2.1 Hz), 7.53-7.54 (1H, m), 8.19 (1H, d, J=2.3 Hz). 
     INDUSTRIAL APPLICABILITY 
     The present invention provides a process for preparing the compound (I) in good yields, said compound being suitable for a production as a medicine on industrial scale.